Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Neoplasms of the CNS

  Free Subscription

Articles published in J Neurooncol

Retrieve available abstracts of 600 articles:
HTML format

Single Articles

    March 2023
  1. QUACH S, Schwartz C, Aumiller M, Foglar M, et al
    Interstitial photodynamic therapy for newly diagnosed glioblastoma.
    J Neurooncol. 2023 Mar 16. doi: 10.1007/s11060-023-04284.
    PubMed     Abstract available

  2. BLEEKER L, Kouwenhoven MCM, de Heer I, Lissenberg-Witte BI, et al
    Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol.
    J Neurooncol. 2023 Mar 15. doi: 10.1007/s11060-023-04285.
    PubMed     Abstract available

  3. YAN M, Lee M, Myrehaug S, Tseng CL, et al
    Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04265.
    PubMed     Abstract available

    Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04288.
    PubMed     Abstract available

  5. KING AL, Roche KN, Leeper HE, Vera E, et al
    Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial.
    J Neurooncol. 2023 Mar 8:1-9. doi: 10.1007/s11060-023-04271.
    PubMed     Abstract available

  6. JUSINO S, Fadul CE, Dillon P
    Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
    J Neurooncol. 2023 Mar 8. doi: 10.1007/s11060-023-04276.
    PubMed     Abstract available

  7. TRIFILETTI DM, Akinyelu T, Burri SH, Jeudy A, et al
    Glioma inadvertently treated with preoperative stereotactic radiosurgery: focusing on safety.
    J Neurooncol. 2023 Mar 6. doi: 10.1007/s11060-023-04278.

  8. MARTIN JA, Hart NH, Bradford N, Naumann F, et al
    Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review.
    J Neurooncol. 2023 Mar 2. doi: 10.1007/s11060-023-04270.
    PubMed     Abstract available

  9. LI C, Guan N, Liu F
    T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
    J Neurooncol. 2023 Mar 1. doi: 10.1007/s11060-023-04257.
    PubMed     Abstract available

    February 2023
  10. TRINGALE KR, Wolden SL, Karajannis M, Haque S, et al
    Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.
    J Neurooncol. 2023 Feb 28. doi: 10.1007/s11060-022-04235.
    PubMed     Abstract available

  11. MOLITERNO J, Brastianos PK
    Journal of Neuro-Oncology, Meningioma issue.
    J Neurooncol. 2023 Feb 27. doi: 10.1007/s11060-023-04251.

  12. PARK YW, Han K, Kim S, Kwon H, et al
    Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-022-04233.
    PubMed     Abstract available

  13. WANG JZ, Nassiri F, Landry AP, Patil V, et al
    The multiomic landscape of meningiomas: a review and update.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-023-04253.
    PubMed     Abstract available

  14. DE CASTRO DG, Sanematsu PI Jr, Pellizzon ACA, Suzuki SH, et al
    Intraoperative radiotherapy for brain metastases: first-stage results of a single-arm, open-label, phase 2 trial.
    J Neurooncol. 2023 Feb 24. doi: 10.1007/s11060-023-04266.
    PubMed     Abstract available

  15. PEI J, Li P, Gao YH, Tian BG, et al
    Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography-mass spectrometry (LC-MS/MS).
    J Neurooncol. 2023 Feb 22. doi: 10.1007/s11060-023-04256.
    PubMed     Abstract available

  16. UHLMANN EJ, Mackel CE, Deforzh E, Rabinovsky R, et al
    Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability.
    J Neurooncol. 2023 Feb 21. doi: 10.1007/s11060-023-04264.
    PubMed     Abstract available

  17. BUSCH N, Zaki PG, Shepard MJ
    Letter to the editor: surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study.
    J Neurooncol. 2023 Feb 21. doi: 10.1007/s11060-023-04267.

  18. NASRALLAH MP, Aldape KD
    Molecular classification and grading of meningioma.
    J Neurooncol. 2023 Feb 18. doi: 10.1007/s11060-022-04228.
    PubMed     Abstract available

  19. ORTIZ-RIVERA J, Nunez R, Kucheryavykh Y, Kucheryavykh L, et al
    The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
    J Neurooncol. 2023 Feb 15. doi: 10.1007/s11060-023-04260.
    PubMed     Abstract available

  20. GHODRATI F, Mekonnen M, Mahgerefteh N, Zhang AB, et al
    Preoperative meningioma vascularity index is associated with significantly increased intraoperative blood loss and greater risk of subtotal resection.
    J Neurooncol. 2023 Feb 14. doi: 10.1007/s11060-023-04259.
    PubMed     Abstract available

  21. HUYNH KA, Coopmans EC, Zamanipoor Najafabadi AH, Dirven L, et al
    Correction to: Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up.
    J Neurooncol. 2023 Feb 13. doi: 10.1007/s11060-023-04255.

  22. SCHRAMM MWJ, Currie S, Lee MT, Livermore LJ, et al
    Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search.
    J Neurooncol. 2023 Feb 9. doi: 10.1007/s11060-023-04246.
    PubMed     Abstract available

  23. HEINZEL A, Mottaghy FM, Filss C, Stoffels G, et al
    The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04254.
    PubMed     Abstract available

  24. MELHEM JM, Tahir A, Calabrese E, Granovskaya I, et al
    Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04248.
    PubMed     Abstract available

  25. FUKUYA Y, Tamura M, Nitta M, Saito T, et al
    Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04244.
    PubMed     Abstract available

  26. WITTEN AJ, Ben-Shalom N, Ellis JA, Boockvar JA, et al
    Optimization of novel exoscopic blue light filter during fluorescence-guided resection of Glioblastoma.
    J Neurooncol. 2023 Feb 6. doi: 10.1007/s11060-022-04231.
    PubMed     Abstract available

  27. SPECKTER H, Palque-Santos S, Mota-Gonzalez R, Bido J, et al
    Can Apparent Diffusion Coefficient (ADC) maps replace Diffusion Tensor Imaging (DTI) maps to predict the volumetric response of meningiomas to Gamma Knife Radiosurgery?
    J Neurooncol. 2023 Feb 6. doi: 10.1007/s11060-023-04243.
    PubMed     Abstract available

  28. PERWEIN T, Giese B, Nussbaumer G, von Bueren AO, et al
    How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
    J Neurooncol. 2023 Feb 1. doi: 10.1007/s11060-023-04241.
    PubMed     Abstract available

  29. PATEL Z, Cho M, Das S
    The role of immune checkpoint inhibitors in patients with intracranial metastatic disease.
    J Neurooncol. 2023;161:469-478.
    PubMed     Abstract available

  30. AK M, Lf N, Gm I, Av K, et al
    Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era.
    J Neurooncol. 2023;161:573-582.
    PubMed     Abstract available

    January 2023
  31. POPPE JP, Machegger L, Steinbacher J, Stefanits H, et al
    Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study.
    J Neurooncol. 2023 Jan 31. doi: 10.1007/s11060-023-04252.
    PubMed     Abstract available

  32. DADARIO NB, Ivan M, Sughrue ME
    Standardizing connectome-based brain tumor surgery through a network-based surgical nomenclature.
    J Neurooncol. 2023 Jan 31. doi: 10.1007/s11060-023-04249.

  33. REUSS DE
    Updates on the WHO diagnosis of IDH-mutant glioma.
    J Neurooncol. 2023 Jan 30. doi: 10.1007/s11060-023-04250.
    PubMed     Abstract available

  34. POTTHOFF AL, Heimann M, Lehmann F, Ilic I, et al
    Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease.
    J Neurooncol. 2023 Jan 25. doi: 10.1007/s11060-023-04242.
    PubMed     Abstract available

  35. COPPIETERS N, Scalisi J, Digregorio M, Leparc L, et al
    Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma.
    J Neurooncol. 2023 Jan 25. doi: 10.1007/s11060-023-04240.
    PubMed     Abstract available

  36. HOLTZMAN AL, Glassman GE, Dagan R, Rao D, et al
    Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.
    J Neurooncol. 2023 Jan 24. doi: 10.1007/s11060-022-04207.
    PubMed     Abstract available

  37. GIUSSANI C, Carrabba G, Rui CB, Chiarello G, et al
    Perilesional resection technique of glioblastoma: intraoperative ultrasound and histological findings of the resection borders in a single center experience.
    J Neurooncol. 2023 Jan 23. doi: 10.1007/s11060-022-04232.
    PubMed     Abstract available

  38. HALKETT GKB, Lobb EA, Phillips JL, McDougall E, et al
    Carer preparedness improved by providing a supportive educational intervention for carers of patients with high-grade glioma: RCT results.
    J Neurooncol. 2023 Jan 19. doi: 10.1007/s11060-023-04239.
    PubMed     Abstract available

  39. DAO TRONG P, Gluszak M, Reuss D, von Deimling A, et al
    Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.
    J Neurooncol. 2023 Jan 17. doi: 10.1007/s11060-022-04230.
    PubMed     Abstract available

  40. ELSAMADICY AA, Reeves BC, Craft S, Sherman JJZ, et al
    A current review of spinal meningiomas: epidemiology, clinical presentation and management.
    J Neurooncol. 2023 Jan 13. doi: 10.1007/s11060-023-04238.
    PubMed     Abstract available

  41. WIJAYA JH, July J, Quintero-Consuegra M, Chadid DP, et al
    A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.
    J Neurooncol. 2023 Jan 12. doi: 10.1007/s11060-023-04237.
    PubMed     Abstract available

  42. SILVERSTEIN JW, Shah HA, Unadkat P, Vilaysom S, et al
    Short and long-term prognostic value of intraoperative motor evoked potentials in brain tumor patients: a case series of 121 brain tumor patients.
    J Neurooncol. 2023 Jan 11. doi: 10.1007/s11060-022-04229.
    PubMed     Abstract available

  43. HUYNH KA, Coopmans EC, Najafabadi AHZ, Dirven L, et al
    Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up.
    J Neurooncol. 2023 Jan 10. doi: 10.1007/s11060-022-04223.
    PubMed     Abstract available

    Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma.
    J Neurooncol. 2023 Jan 6. doi: 10.1007/s11060-022-04222.
    PubMed     Abstract available

  45. EICHKORN T, Lischalk JW, Horner-Rieber J, Deng M, et al
    Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.
    J Neurooncol. 2023 Jan 4. doi: 10.1007/s11060-022-04217.
    PubMed     Abstract available

  46. SUAREZ-MEADE P, Watanabe F, Ruiz-Garcia H, Rafferty SB, et al
    SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.
    J Neurooncol. 2023 Jan 3:1-10. doi: 10.1007/s11060-022-04205.
    PubMed     Abstract available

  47. MAYO ZS, Halima A, Broughman JR, Smile TD, et al
    Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis.
    J Neurooncol. 2023;161:23-31.
    PubMed     Abstract available

  48. LIN YY, Wu HM, Yang HC, Chen CJ, et al
    Stereotactic radiosurgery for pituitary and cavernous sinus metastases.
    J Neurooncol. 2023;161:175-184.
    PubMed     Abstract available

  49. JOHNSON KJ, Barnes JM, Delavar A, O'Connell CP, et al
    Facility patient volume and survival among individuals diagnosed with malignant central nervous system tumors.
    J Neurooncol. 2023;161:117-126.
    PubMed     Abstract available

  50. WELLER J, Schafer N, Schaub C, Tzaridis T, et al
    Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
    J Neurooncol. 2023;161:147-153.
    PubMed     Abstract available

  51. KUMAR S, Islim AI, Moon R, Millward CP, et al
    Long term quality of life outcomes following surgical resection alone for benign paediatric intracranial tumours.
    J Neurooncol. 2023;161:77-84.
    PubMed     Abstract available

  52. BUTENSCHOEN VM, Schwendner M, Hubertus V, Onken J, et al
    Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: a multicenter retrospective case series.
    J Neurooncol. 2023;161:107-115.
    PubMed     Abstract available

  53. CARLOS-ESCALANTE JA, Mejia-Perez SI, Soto-Reyes E, Guerra-Calderas L, et al
    Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
    J Neurooncol. 2023;161:165-174.
    PubMed     Abstract available

    December 2022
  54. QIU X, Gao J, Hu J, Yang J, et al
    Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.
    J Neurooncol. 2022 Dec 30. doi: 10.1007/s11060-022-04202.
    PubMed     Abstract available

  55. SLOAN AE, Nock CJ, Ye X, Buerki R, et al
    ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04193.
    PubMed     Abstract available

  56. SOMMA T, Bove I, Vitulli F, Cappabianca P, et al
    Management and treatment of brain tumors during pregnancy: an Italian survey.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04215.
    PubMed     Abstract available

  57. WOLLRING MM, Werner JM, Ceccon G, Lohmann P, et al
    Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04218.
    PubMed     Abstract available

  58. HOPPER A, Salans M, Karunamuni R, Hattangadi-Gluth JA, et al
    Neurocognitive considerations in the treatment of meningioma with radiation therapy: applications for quantitative neuroimaging and precision radiation medicine.
    J Neurooncol. 2022 Dec 26. doi: 10.1007/s11060-022-04175.
    PubMed     Abstract available

  59. ENTENMANN CJ, Bubenikova A, Blazkova J Jr, Zapotocky M, et al
    Evaluation of the growth rates and related prognostic factors in radiation-induced meningiomas.
    J Neurooncol. 2022 Dec 24. doi: 10.1007/s11060-022-04209.
    PubMed     Abstract available

  60. SINGH J, Sharma R, Shukla N, Narwal P, et al
    DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
    J Neurooncol. 2022 Dec 24. doi: 10.1007/s11060-022-04220.
    PubMed     Abstract available

  61. USUZAKI T, Takahashi K
    Comment on "Sex as a prognostic factor in adult‑type diffuse gliomas: an integrated clinical and molecular analysis according to 2021 WHO classification".
    J Neurooncol. 2022 Dec 22. doi: 10.1007/s11060-022-04224.

  62. LIU CW, Yang HC, Chiang CL, Shen CI, et al
    Leukoencephalopathy in patients with brain metastases who received radiosurgery with or without whole brain radiotherapy.
    J Neurooncol. 2022 Dec 22. doi: 10.1007/s11060-022-04210.
    PubMed     Abstract available

  63. KESHWARA SM, Gillespie CS, Mustafa MA, George AM, et al
    Quality of life outcomes in incidental and operated meningiomas (QUALMS): a cross-sectional cohort study.
    J Neurooncol. 2022 Dec 16. doi: 10.1007/s11060-022-04198.
    PubMed     Abstract available

  64. SHI W, Wang Y, Xia W, Liu B, et al
    Brain metastases from small cell lung cancer and non-small cell lung cancer: comparison of spatial distribution and identification of metastatic risk regions.
    J Neurooncol. 2022 Dec 15. doi: 10.1007/s11060-022-04211.
    PubMed     Abstract available

  65. STEINER G, Galli R, Preusse G, Michen S, et al
    A new approach for clinical translation of infrared spectroscopy: exploitation of the signature of glioblastoma for general brain tumor recognition.
    J Neurooncol. 2022 Dec 12. doi: 10.1007/s11060-022-04204.
    PubMed     Abstract available

  66. THOMMEN R, Kazim SF, Rumalla K, Kassicieh AJ, et al
    Correction to: Preoperative frailty measured by risk analysis index predicts complications and poor discharge outcomes after Brain Tumor Resection in a large multi-center analysis.
    J Neurooncol. 2022 Dec 12. doi: 10.1007/s11060-022-04212.

  67. SINGNURKAR A, Poon R, Detsky J
    18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis.
    J Neurooncol. 2022 Dec 11. doi: 10.1007/s11060-022-04201.
    PubMed     Abstract available

  68. CHEN YC, Yang HC, Chiang CL, Chen CJ, et al
    Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center.
    J Neurooncol. 2022 Dec 5. doi: 10.1007/s11060-022-04153.
    PubMed     Abstract available

  69. KIM D, Chang WI, Byun HK, Kim IA, et al
    Dose-response relationship in patients with newly diagnosed atypical meningioma treated with adjuvant radiotherapy.
    J Neurooncol. 2022 Dec 5. doi: 10.1007/s11060-022-04206.
    PubMed     Abstract available

  70. ALBERS EAC, de Ruiter MB, van de Poll-Franse LV, Merckel LG, et al
    Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.
    J Neurooncol. 2022 Dec 1. doi: 10.1007/s11060-022-04185.
    PubMed     Abstract available

  71. CHOJAK R, Kozba-Gosztyla M, Polanska K, Rojek M, et al
    Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis.
    J Neurooncol. 2022;160:753-761.
    PubMed     Abstract available

  72. PENNINGTON Z, Mikula AL, Lakomkin N, Meyer FB, et al
    Impact of tumor-associated syrinx on outcomes following resection of primary ependymomas of the spinal cord.
    J Neurooncol. 2022;160:725-733.
    PubMed     Abstract available

  73. TOMASINO B, Guarracino I, Pauletto G, Pez S, et al
    Performing real time neuropsychological testing during awake craniotomy: are dexmedetomidine or propofol the same? A preliminary report.
    J Neurooncol. 2022;160:707-716.
    PubMed     Abstract available

  74. SLEURS C, Zegers CML, Compter I, Dijkstra J, et al
    Neurocognition in adults with intracranial tumors: does location really matter?
    J Neurooncol. 2022;160:619-629.
    PubMed     Abstract available

    November 2022
  75. KIM W, Ghodrati F, Mozaffari K, Samarage HM, et al
    Endoscopic endonasal approach for resection of a recurrent spheno-orbital meningioma resulting in complete resolution of visual symptoms: A case report and review of literature.
    J Neurooncol. 2022 Nov 29. doi: 10.1007/s11060-022-04141.
    PubMed     Abstract available

  76. KHRISTOV V, Nesterova D, Trifoi M, Clegg T, et al
    Plasma IL13Ralpha2 as a novel liquid biopsy biomarker for glioblastoma.
    J Neurooncol. 2022 Nov 27. doi: 10.1007/s11060-022-04196.
    PubMed     Abstract available

  77. VASAN V, Dullea JT, Devarajan A, Ali M, et al
    NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    J Neurooncol. 2022 Nov 27. doi: 10.1007/s11060-022-04197.
    PubMed     Abstract available

  78. SVENJEBY C, Carstam L, Werlenius K, Bontell TO, et al
    Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.
    J Neurooncol. 2022 Nov 25. doi: 10.1007/s11060-022-04136.
    PubMed     Abstract available

  79. ROACH JR, Plaha P, McGowan DR, Higgins GS, et al
    The role of [(18)F]fluorodopa positron emission tomography in grading of gliomas.
    J Neurooncol. 2022 Nov 24. doi: 10.1007/s11060-022-04177.
    PubMed     Abstract available

  80. MIYAGISHIMA DF, Moliterno J, Claus E, Gunel M, et al
    Hormone therapies in meningioma-where are we?
    J Neurooncol. 2022 Nov 23. doi: 10.1007/s11060-022-04187.
    PubMed     Abstract available

  81. ELSHEIKH M, Bridgman E, Lavrador JP, Lammy S, et al
    Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review & meta-analysis.
    J Neurooncol. 2022 Nov 21. doi: 10.1007/s11060-022-04192.
    PubMed     Abstract available

  82. KIM SJ, Park SJ, Park J, Cho HJ, et al
    Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04189.
    PubMed     Abstract available

  83. GAMBOA NT, Crabb B, Henson JC, Cole KL, et al
    High-grade glioma imaging volumes and survival: a single-institution analysis of 101 patients after resection using intraoperative MRI.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04159.
    PubMed     Abstract available

  84. TEN CATE C, Huijs SMH, Willemsen ACH, Pasmans RCOS, et al
    Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04180.
    PubMed     Abstract available

  85. ISLIM AI, Lee JX, Mustafa MA, Millward CP, et al
    Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study.
    J Neurooncol. 2022 Nov 15. pii: 10.1007/s11060-022-04184.
    PubMed     Abstract available

  86. RAJKUMAR S, Liang Y, Wegner RE, Shepard MJ, et al
    Utilization of neoadjuvant stereotactic radiosurgery for the treatment of brain metastases requiring surgical resection: a topic review.
    J Neurooncol. 2022 Nov 14. pii: 10.1007/s11060-022-04190.
    PubMed     Abstract available

  87. SHAH HA, Leskinen S, Khilji H, Narayan V, et al
    Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review.
    J Neurooncol. 2022 Nov 12. pii: 10.1007/s11060-022-04188.
    PubMed     Abstract available

  88. SATRAGNO C, Verrico A, Giannelli F, Ferrero A, et al
    High dose craniospinal irradiation as independent risk factor of permanent alopecia in childhood medulloblastoma survivors: cohort study and literature review.
    J Neurooncol. 2022 Nov 12. pii: 10.1007/s11060-022-04186.
    PubMed     Abstract available

  89. WANG J, Huang Y, Zhao F, Chen J, et al
    Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04162.
    PubMed     Abstract available

  90. CHIDLEY P, Shanker M, Phillips C, Haghighi N, et al
    Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04151.
    PubMed     Abstract available

  91. ALI AS, Lombardo J, Niazi MZ, Miller RC, et al
    Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04146.
    PubMed     Abstract available

  92. QUIJANO-RUBIO C, Silginer M, Weller M
    CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04137.
    PubMed     Abstract available

  93. SHI DD, Anand S, Abdullah KG, McBrayer SK, et al
    DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
    J Neurooncol. 2022 Nov 9. pii: 10.1007/s11060-022-04172.
    PubMed     Abstract available

  94. ZHOU S, Ren F, Li C, Jiang L, et al
    Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
    J Neurooncol. 2022 Nov 8. pii: 10.1007/s11060-022-04182.
    PubMed     Abstract available

  95. MADER MM, Deuter D, Sauvigny T, Borchert P, et al
    Diffusion tensor imaging changes in patients with glioma-associated seizures.
    J Neurooncol. 2022 Nov 7. pii: 10.1007/s11060-022-04139.
    PubMed     Abstract available

  96. ROY LO, Lemelin M, Blanchette M, Poirier MB, et al
    Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates.
    J Neurooncol. 2022 Nov 7. pii: 10.1007/s11060-022-04179.
    PubMed     Abstract available

  97. LANIER CM, Pearce J, Isom S, Xing F, et al
    Long term survivors of stereotactic radiosurgery for brain metastases: do distant brain failures reach a plateau and what factors are associated with a brain metastasis velocity of zero?
    J Neurooncol. 2022 Nov 6. pii: 10.1007/s11060-022-04183.
    PubMed     Abstract available

  98. HUA L, Ren L, Wu Q, Deng J, et al
    Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04169.
    PubMed     Abstract available

  99. BRAUCHITSCH SV, Strzelczyk A, Rosenow F, Neuhaus E, et al
    High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04133.
    PubMed     Abstract available

  100. GALLET C, Clavreul A, Morandi X, Delion M, et al
    What surgical approach for left-sided eloquent glioblastoma: biopsy, resection under general anesthesia or awake craniotomy?
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04163.
    PubMed     Abstract available

  101. CHOTAI S, Tang AR, Gupta R, Guidry BS, et al
    Matched case-control analysis of outcomes following surgical resection of incidental meningioma.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04167.
    PubMed     Abstract available

  102. ZENG L, Li H, Chen R, Yang H, et al
    Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis.
    J Neurooncol. 2022 Nov 2. pii: 10.1007/s11060-022-04170.
    PubMed     Abstract available

  103. GORODEZKI D, Zipfel J, Queudeville M, Sosa J, et al
    Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis.
    J Neurooncol. 2022 Nov 1. pii: 10.1007/s11060-022-04176.
    PubMed     Abstract available

  104. MCKENZIE G, Gaskins J, Rattani A, Oliver A, et al
    Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases.
    J Neurooncol. 2022 Nov 1. pii: 10.1007/s11060-022-04178.
    PubMed     Abstract available

  105. JIA H, Zhang P, Gu G, Li T, et al
    Brainstem tumors may increase the impairment of behavioral emotional cognition in children.
    J Neurooncol. 2022;160:423-432.
    PubMed     Abstract available

  106. IGLESIAS P, Biagetti B, Araujo-Castro M, Alcazar V, et al
    Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
    J Neurooncol. 2022;160:351-359.
    PubMed     Abstract available

  107. RAGHIB MF, Salim A, Angez M, Ghazi SM, et al
    Prognostic implication of size on outcomes of pituitary macroadenoma: a comparative analysis of giant adenoma with non-giant macroadenoma.
    J Neurooncol. 2022;160:491-496.
    PubMed     Abstract available

  108. SHE L, Deng D, Su L, Liu C, et al
    Comparison of surgery with or without adjuvant radiotherapy in treating central neurocytoma: a single-center retrospective real-world study.
    J Neurooncol. 2022;160:455-462.
    PubMed     Abstract available

  109. WEBB M, Johnson DR, Mahajan A, Brown P, et al
    Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis.
    J Neurooncol. 2022;160:527-534.
    PubMed     Abstract available

    October 2022
  110. THOMMEN R, Kazim SF, Rumalla K, Kassicieh AJ, et al
    Preoperative frailty measured by risk analysis index predicts complications and poor discharge outcomes after Brain Tumor Resection in a large multi-center analysis.
    J Neurooncol. 2022 Oct 31. pii: 10.1007/s11060-022-04135.
    PubMed     Abstract available

  111. CHEN WC, Perlow HK, Choudhury A, Nguyen MP, et al
    Radiotherapy for meningiomas.
    J Neurooncol. 2022 Oct 31. pii: 10.1007/s11060-022-04171.
    PubMed     Abstract available

  112. RUDA R, Bruno F, Pellerino A, Pronello E, et al
    Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
    J Neurooncol. 2022 Oct 30. pii: 10.1007/s11060-022-04155.
    PubMed     Abstract available

  113. TSUJI S, Nakamura S, Shoda K, Yamada T, et al
    NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    J Neurooncol. 2022 Oct 29. pii: 10.1007/s11060-022-04154.
    PubMed     Abstract available

  114. SHARMA M, Wang D, Palmisciano P, Ugiliweneza B, et al
    Is intraoperative MRI use in malignant brain tumor surgery a health care burden? A matched analysis of MarketScan Database.
    J Neurooncol. 2022 Oct 26. pii: 10.1007/s11060-022-04142.
    PubMed     Abstract available

  115. OHNO M, Kitano S, Satomi K, Yoshida A, et al
    Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.
    J Neurooncol. 2022 Oct 25. pii: 10.1007/s11060-022-04165.
    PubMed     Abstract available

  116. BATTISTA F, Muscas G, Dinoi F, Gadda D, et al
    Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients.
    J Neurooncol. 2022 Oct 23. pii: 10.1007/s11060-022-04166.
    PubMed     Abstract available

  117. CARSTAM L, Ryden I, Jakola AS
    Seizures in patients with IDH-mutated lower grade gliomas.
    J Neurooncol. 2022 Oct 18. pii: 10.1007/s11060-022-04158.
    PubMed     Abstract available

  118. MAHMOODIFAR S, Pangal DJ, Cardinal T, Craig D, et al
    A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes.
    J Neurooncol. 2022 Oct 16. pii: 10.1007/s11060-022-04147.
    PubMed     Abstract available

  119. PEASE M, Gersey ZC, Ak M, Elakkad A, et al
    Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients.
    J Neurooncol. 2022 Oct 14. pii: 10.1007/s11060-022-04150.
    PubMed     Abstract available

  120. HUI C, Qu V, Wang JY, von Eyben R, et al
    Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
    J Neurooncol. 2022 Oct 13. pii: 10.1007/s11060-022-04145.
    PubMed     Abstract available

  121. MARQUEZ J, Schmidt M, Bowers CA
    Letter: Does the "hospital frailty risk score" measure preoperative frailty for craniopharyngioma surgery?
    J Neurooncol. 2022 Oct 12. pii: 10.1007/s11060-022-04157.

  122. RAZAVIAN NB, Helis CA, Laxton A, Tatter S, et al
    Outcomes of radiation-induced meningiomas treated with stereotactic radiosurgery.
    J Neurooncol. 2022 Oct 12. pii: 10.1007/s11060-022-04156.
    PubMed     Abstract available

  123. LU G, Zhu P, Rao M, Linendoll N, et al
    Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    J Neurooncol. 2022 Oct 6. pii: 10.1007/s11060-022-04144.
    PubMed     Abstract available

  124. MAIR MJ, Berghoff AS, Brastianos PK, Preusser M, et al
    Emerging systemic treatment options in meningioma.
    J Neurooncol. 2022 Oct 1. pii: 10.1007/s11060-022-04148.
    PubMed     Abstract available

  125. CIOFFI G, Waite KA, Edelson JL, Kruchko C, et al
    Changes in survival over time for primary brain and other CNS tumors in the United States, 2004-2017.
    J Neurooncol. 2022;160:209-219.
    PubMed     Abstract available

  126. WELLER J, Katzendobler S, Blobner J, Thiele F, et al
    Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
    J Neurooncol. 2022;160:149-158.
    PubMed     Abstract available

  127. SURUGA Y, Satomi K, Otani Y, Fujii K, et al
    The utility of DNA methylation analysis in elderly patients with pilocytic astrocytoma morphology.
    J Neurooncol. 2022;160:179-189.
    PubMed     Abstract available

  128. MALAIZE H, Laigle-Donadey F, Riche M, Marijon P, et al
    Roles and outcomes of stereotactic biopsy for adult patients with brainstem lesion.
    J Neurooncol. 2022;160:159-170.
    PubMed     Abstract available

  129. HONG KT, Han JW, Fuji H, Byun HK, et al
    Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors.
    J Neurooncol. 2022;160:41-53.
    PubMed     Abstract available

  130. PALMISCIANO P, Watanabe G, Conching A, Ogasawara C, et al
    Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials.
    J Neurooncol. 2022;160:79-100.
    PubMed     Abstract available

    September 2022
  131. ABDALLAH HM, Mallela AN, Wei Z, Abou-Al-Shaar H, et al
    Gamma Knife radiosurgery for meningiomas of the confluence of the falx and tentorium.
    J Neurooncol. 2022 Sep 20. pii: 10.1007/s11060-022-04125.
    PubMed     Abstract available

  132. KOIDE Y, Nagai N, Miyauchi R, Kitagawa T, et al
    Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study.
    J Neurooncol. 2022 Sep 16. pii: 10.1007/s11060-022-04132.
    PubMed     Abstract available

  133. SCHACKERT G, Lenk M, Kirsch M, Hennig S, et al
    Surgical results of 158 petroclival meningiomas with special focus on standard craniotomies.
    J Neurooncol. 2022 Sep 14. pii: 10.1007/s11060-022-04105.
    PubMed     Abstract available

  134. SU H, Hailin Z, Dongdong L, Jiang Y, et al
    Long non-coding RNA LINC01018 inhibits human glioma cell proliferation and metastasis by directly targeting miRNA-182-5p.
    J Neurooncol. 2022 Sep 12. pii: 10.1007/s11060-022-04113.
    PubMed     Abstract available

  135. LU VM, Niazi TN
    Racial disparities in pediatric malignant glioma management: current state of affairs in the United States.
    J Neurooncol. 2022 Sep 8. pii: 10.1007/s11060-022-04130.
    PubMed     Abstract available

  136. ABDELRAHMAN A, Negroni C, Sahm F, Adams CL, et al
    miR-497 and 219 in blood aid meningioma classification.
    J Neurooncol. 2022 Sep 8. pii: 10.1007/s11060-022-04126.
    PubMed     Abstract available

  137. SAMOYEAU T, Provost C, Roux A, Legrand L, et al
    Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
    J Neurooncol. 2022 Sep 6. pii: 10.1007/s11060-022-04124.
    PubMed     Abstract available

  138. DOS SANTOS SILVA J, Schreiner CA, de Lima L, Brigido CEPL, et al
    Volumetric measurement of intracranial meningiomas: a comparison between linear, planimetric, and machine learning with multiparametric voxel-based morphometry methods.
    J Neurooncol. 2022 Sep 5. pii: 10.1007/s11060-022-04127.
    PubMed     Abstract available

  139. SHIDOH S, Savjani RR, Cho NS, Ullman HE, et al
    Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
    J Neurooncol. 2022 Sep 2. pii: 10.1007/s11060-022-04123.
    PubMed     Abstract available

  140. TAKAMI H, Graffeo CS, Perry A, Brown DA, et al
    Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas.
    J Neurooncol. 2022;159:221-231.
    PubMed     Abstract available

  141. SHIBAHARA I, Shibahara Y, Hagiwara H, Watanabe T, et al
    Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
    J Neurooncol. 2022;159:425-435.
    PubMed     Abstract available

  142. GELHARD S, Maxwell A, Colman H, Cohen AL, et al
    Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis.
    J Neurooncol. 2022;159:293-300.
    PubMed     Abstract available

  143. ALIOUAT I, Moiraghi A, Simboli GA, Birsen R, et al
    Accuracy and safety of 101 consecutives neurosurgical procedures for newly diagnosed central nervous system lymphomas: a single-institution experience.
    J Neurooncol. 2022;159:347-358.
    PubMed     Abstract available

  144. GARZIO K, McElroy K, Grossman S, Holdhoff M, et al
    Safety of temozolomide use in adult patients with renal dysfunction.
    J Neurooncol. 2022;159:591-596.
    PubMed     Abstract available

  145. KALAWI AZ, Malicki DM, Abdullaev Z, Pratt DW, et al
    The role of methylation profiling in histologically diagnosed neurocytoma: a case series.
    J Neurooncol. 2022;159:725-733.
    PubMed     Abstract available

  146. PLANT-FOX AS, Suzuki T, Diaz Coronado RY, Epelman S, et al
    An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry.
    J Neurooncol. 2022;159:563-570.
    PubMed     Abstract available

    August 2022
  147. KUMAR TS, Afnan WM, Chan CY, Audrey C, et al
    Impact of seizures and antiseizure medication on survival in patients with glioma.
    J Neurooncol. 2022 Aug 29. pii: 10.1007/s11060-022-04108.
    PubMed     Abstract available

  148. SAGBERG LM, Fyllingen EH, Hansen TI, Strand PS, et al
    Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study.
    J Neurooncol. 2022 Aug 27. pii: 10.1007/s11060-022-04120.
    PubMed     Abstract available

  149. YAN M, Holden L, Wang M, Soliman H, et al
    Gamma knife icon based hypofractionated stereotactic radiosurgery (GKI-HSRS) for brain metastases: impact of dose and volume.
    J Neurooncol. 2022 Aug 24. pii: 10.1007/s11060-022-04115.
    PubMed     Abstract available

  150. IMBER BS, Young RJ, Beal K, Reiner AS, et al
    Correction to: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases.
    J Neurooncol. 2022 Aug 23. pii: 10.1007/s11060-022-04121.

  151. WANG M, Zhang Y, Shi W, Zhu R, et al
    Frameless robot-assisted stereotactic biopsy: an effective and minimally invasive technique for pediatric diffuse intrinsic pontine gliomas.
    J Neurooncol. 2022 Aug 23. pii: 10.1007/s11060-022-04122.
    PubMed     Abstract available

  152. GUNJUR A, Balasubramanian A, Hafeez U, Menon S, et al
    Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.
    J Neurooncol. 2022 Aug 22. pii: 10.1007/s11060-022-04119.

  153. KIM M, Kim S, Park YW, Han K, et al
    Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
    J Neurooncol. 2022 Aug 21. pii: 10.1007/s11060-022-04114.
    PubMed     Abstract available

  154. PARTIN RE, Wogksch MD, Dhaduk R, Ashford JM, et al
    Physical function, body mass index, and fitness outcomes in children, adolescents, and emerging adults with craniopharyngioma from proton therapy through five years of follow-up.
    J Neurooncol. 2022 Aug 20. pii: 10.1007/s11060-022-04116.
    PubMed     Abstract available

  155. SIMOES PADILLA C, Ho VKY, van der Strate IH, Leenders WPJ, et al
    Prognostic factors among patients with brain metastases from cancer of unknown primary site.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04106.
    PubMed     Abstract available

  156. MA J, Tian Y, Hao S, Zheng L, et al
    Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04111.
    PubMed     Abstract available

  157. BIN-ALAMER O, Alnefaie N, Qedair J, Chaudhary A, et al
    Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04112.
    PubMed     Abstract available

  158. LIAO HR, Chiang CL, Shen CI, Chen CJ, et al
    EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04110.
    PubMed     Abstract available

  159. LI S, Wu B, Xiao Y, Wu J, et al
    Exploring the pathological relationships between adamantinomatous craniopharyngioma and contiguous structures with tumor origin.
    J Neurooncol. 2022 Aug 8. pii: 10.1007/s11060-022-04084.
    PubMed     Abstract available

  160. HOLLINGWORTH M, Zacharoulis S
    Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04077.
    PubMed     Abstract available

  161. GUNJUR A, Balasubramanian A, Hafeez U, Menon S, et al
    Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04092.
    PubMed     Abstract available

  162. CLIMANS SA, Mason WP, Grunfeld E, Chan K, et al
    Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04109.
    PubMed     Abstract available

  163. PONTORIERO A, Critelli P, Conti A, Cardali S, et al
    The "Combo" radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis.
    J Neurooncol. 2022 Aug 4. pii: 10.1007/s11060-022-04107.
    PubMed     Abstract available

  164. LOHKAMP LN, Kulkarni AV, Drake JM, Rutka JT, et al
    Preservation of endocrine function after Ommaya reservoir insertion in children with cystic craniopharyngioma.
    J Neurooncol. 2022 Aug 4. pii: 10.1007/s11060-022-04099.
    PubMed     Abstract available

  165. ONISHI S, Yamasaki F, Amatya VJ, Takayasu T, et al
    Characteristics and therapeutic strategies of radiation-induced glioma: case series and comprehensive literature review.
    J Neurooncol. 2022 Aug 3. pii: 10.1007/s11060-022-04090.
    PubMed     Abstract available

  166. TANG AR, Chotai S, Grisham CJ, Guidry BS, et al
    Outcomes following surgical resection of cystic intracranial meningiomas.
    J Neurooncol. 2022 Aug 3. pii: 10.1007/s11060-022-04096.
    PubMed     Abstract available

  167. VUONG HG, Dunn IF
    Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
    J Neurooncol. 2022;159:195-200.
    PubMed     Abstract available

  168. DESJARDINS C, Larrieu-Ciron D, Choquet S, Mokhtari K, et al
    Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
    J Neurooncol. 2022;159:151-161.
    PubMed     Abstract available

  169. ID SAID B, Chen H, Jerzak KJ, Warner E, et al
    Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer.
    J Neurooncol. 2022;159:177-183.
    PubMed     Abstract available

  170. RAKOVEC M, Khalafallah AM, Wei O, Day D, et al
    A consensus definition of supratotal resection for anatomically distinct primary glioblastoma: an AANS/CNS Section on Tumors survey of neurosurgical oncologists.
    J Neurooncol. 2022 Aug 1. pii: 10.1007/s11060-022-04048.
    PubMed     Abstract available

    July 2022
  171. IMBER BS, Young RJ, Beal K, Reiner AS, et al
    Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases.
    J Neurooncol. 2022 Jul 27. pii: 10.1007/s11060-022-04101.
    PubMed     Abstract available

  172. DAZA-OVALLE A, Bin-Alamer O, Flickinger J, Niranjan A, et al
    Outcomes after gamma knife radiosurgery for intraventricular meningiomas.
    J Neurooncol. 2022 Jul 26. pii: 10.1007/s11060-022-04091.
    PubMed     Abstract available

  173. DO TH, Howard MA, Palzer EF, Huling JD, et al
    Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).
    J Neurooncol. 2022 Jul 23. pii: 10.1007/s11060-022-04093.
    PubMed     Abstract available

  174. LUGER AL, Konig S, Samp PF, Urban H, et al
    Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
    J Neurooncol. 2022 Jul 21. pii: 10.1007/s11060-022-04049.
    PubMed     Abstract available

  175. YOGENDRAN LV, Kalelioglu T, Donahue JH, Ahmad H, et al
    The landscape of brain tumor mimics in neuro-oncology practice.
    J Neurooncol. 2022 Jul 20. pii: 10.1007/s11060-022-04087.
    PubMed     Abstract available

  176. MENDEZ VALDEZ MJ, Lu VM, Kim E, Rivas SR, et al
    Glioblastoma multiforme in patients with human immunodeficiency virus: an integrated review and analysis.
    J Neurooncol. 2022 Jul 20. pii: 10.1007/s11060-022-04095.
    PubMed     Abstract available

  177. MOASSEFI M, Faghani S, Conte GM, Kowalchuk RO, et al
    A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    J Neurooncol. 2022 Jul 19. pii: 10.1007/s11060-022-04080.
    PubMed     Abstract available

  178. MULLER M, Winz O, Gutsche R, Leijenaar RTH, et al
    Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.
    J Neurooncol. 2022 Jul 19. pii: 10.1007/s11060-022-04089.
    PubMed     Abstract available

  179. HAGIWARA A, Schlossman J, Shabani S, Raymond C, et al
    Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
    J Neurooncol. 2022 Jul 17. pii: 10.1007/s11060-022-04088.
    PubMed     Abstract available

  180. MELNICK KF, Miller P, Carmichael E, McGrath K, et al
    The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
    J Neurooncol. 2022 Jul 15. pii: 10.1007/s11060-022-04083.
    PubMed     Abstract available

  181. DE BRITO RANGEL J, Giglio AG, Cardozo CL, Bergmann A, et al
    Prognostic factors for brain metastasis in women presenting cervical cancer.
    J Neurooncol. 2022 Jul 14. pii: 10.1007/s11060-022-04082.
    PubMed     Abstract available

  182. RECKER MJ, Kuo CC, Prasad D, Attwood K, et al
    Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018.
    J Neurooncol. 2022 Jul 11. pii: 10.1007/s11060-022-04085.
    PubMed     Abstract available

  183. FUJITA Y, Nunez-Rubiano L, Dono A, Bellman A, et al
    IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    J Neurooncol. 2022 Jul 11. pii: 10.1007/s11060-022-04060.
    PubMed     Abstract available

  184. KAWASHIMA M, Akabane A, Noda R, Segawa M, et al
    Interfractional change of tumor volume during fractionated stereotactic radiotherapy using gamma knife for brain metastases.
    J Neurooncol. 2022 Jul 9. pii: 10.1007/s11060-022-04075.
    PubMed     Abstract available

  185. MASSIMINO M, Vennarini S, Barretta F, Colombo F, et al
    How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.
    J Neurooncol. 2022 Jul 9. pii: 10.1007/s11060-022-04079.
    PubMed     Abstract available

  186. SCHLOMER S, Felsberg J, Pertz M, Hentschel B, et al
    Mid-term treatment-related cognitive sequelae in glioma patients.
    J Neurooncol. 2022 Jul 7. pii: 10.1007/s11060-022-04044.
    PubMed     Abstract available

  187. PEI YY, Zhang Y, Liu ZR, He Y, et al
    Lactate dehydrogenase as promising marker for prognosis of brain metastasis.
    J Neurooncol. 2022 Jul 7. pii: 10.1007/s11060-022-04070.
    PubMed     Abstract available

  188. TOBOCHNIK S, Lapinskas E, Vogelzang J, Ligon KL, et al
    Correction to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.
    J Neurooncol. 2022 Jul 6. pii: 10.1007/s11060-022-04086.

  189. BUNEVICIUS A, Donovan L, Sheehan J
    Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review.
    J Neurooncol. 2022 Jul 4. pii: 10.1007/s11060-022-04067.
    PubMed     Abstract available

  190. SUZUKI H, Ono T, Koyota S, Takahashi M, et al
    Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.
    J Neurooncol. 2022 Jul 2. pii: 10.1007/s11060-022-04074.
    PubMed     Abstract available

  191. MALDAR AN, Pattankar S, Misra BK, Chauhan PH, et al
    Long-term hormonal and imaging outcomes of adjunctive gamma knife radiosurgery in non-functioning pituitary adenomas: a single center experience.
    J Neurooncol. 2022;158:423-433.
    PubMed     Abstract available

  192. BANDER ED, Knisely JPS, Schwartz TH
    Brachytherapy for central nervous system tumors.
    J Neurooncol. 2022;158:393-403.
    PubMed     Abstract available

    June 2022
  193. DE LAURENTIS C, Cristaldi PMF, Rebora P, Valsecchi MG, et al
    Posterior fossa syndrome in a population of children and young adults with medulloblastoma: a retrospective, multicenter Italian study on incidence and pathophysiology in a histologically homogeneous and consecutive series of 136 patients.
    J Neurooncol. 2022 Jun 29. pii: 10.1007/s11060-022-04072.
    PubMed     Abstract available

  194. WANG F, Cathcart SJ, DiMaio DJ, Zhao N, et al
    Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.
    J Neurooncol. 2022 Jun 26. pii: 10.1007/s11060-022-04053.
    PubMed     Abstract available

  195. PALMER JD, Perlow HK, Matsui JK, Ho C, et al
    Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis.
    J Neurooncol. 2022 Jun 25. pii: 10.1007/s11060-022-04073.
    PubMed     Abstract available

  196. GREER HR, Miller K, Samay S, Nellan A, et al
    Investigation of white blood cell characteristics in cerebrospinal fluid samples at pediatric brain tumor diagnosis.
    J Neurooncol. 2022 Jun 22. pii: 10.1007/s11060-022-04065.
    PubMed     Abstract available

  197. PETERSON R, Kandregula S, Jee E, Guthikonda B, et al
    Utility of hospital frailty risk score for predicting postoperative outcomes in craniopharyngioma.
    J Neurooncol. 2022 Jun 20. pii: 10.1007/s11060-022-04056.
    PubMed     Abstract available

  198. WIJAYA JH, Arjuna YYE, July J
    The role of stereotactic radiosurgery in the management of petroclival meningioma: a systematic review.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04041.
    PubMed     Abstract available

  199. BRACCI PM, Rice T, Hansen HM, Francis SS, et al
    Pre-surgery immune profiles of adult glioma patients.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04047.
    PubMed     Abstract available

  200. WERNER JM, Wolf L, Tscherpel C, Bauer EK, et al
    Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04066.
    PubMed     Abstract available

  201. SPECKTER H, Radulovic M, Trivodaliev K, Vranes V, et al
    MRI radiomics in the prediction of the volumetric response in meningiomas after gamma knife radiosurgery.
    J Neurooncol. 2022 Jun 17. pii: 10.1007/s11060-022-04063.
    PubMed     Abstract available

  202. TOBOCHNIK S, Lapinskas E, Vogelzang J, Ligon KL, et al
    Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.
    J Neurooncol. 2022 Jun 17. pii: 10.1007/s11060-022-04059.
    PubMed     Abstract available

  203. PRADHAN A, Mozaffari K, Ghodrati F, Everson RG, et al
    Modern surgical management of incidental gliomas.
    J Neurooncol. 2022 Jun 15. pii: 10.1007/s11060-022-04045.
    PubMed     Abstract available

  204. WELLER J, Schafer N, Schaub C, Potthoff AL, et al
    Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
    J Neurooncol. 2022 Jun 15. pii: 10.1007/s11060-022-04046.
    PubMed     Abstract available

  205. RAMOS-FRESNEDO A, Domingo RA, Perez-Vega C, Pullen MW, et al
    The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study.
    J Neurooncol. 2022 Jun 14. pii: 10.1007/s11060-022-04040.
    PubMed     Abstract available

  206. PALMISCIANO P, Haider AS, Balasubramanian K, D'Amico RS, et al
    The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials.
    J Neurooncol. 2022 Jun 13. pii: 10.1007/s11060-022-04050.
    PubMed     Abstract available

  207. AUTRY AW, Lafontaine M, Jalbert L, Phillips E, et al
    Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    J Neurooncol. 2022 Jun 8. pii: 10.1007/s11060-022-04042.
    PubMed     Abstract available

  208. MICHEL A, Dinger TF, Santos AN, Pierscianek D, et al
    Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery.
    J Neurooncol. 2022 Jun 7. pii: 10.1007/s11060-022-04043.
    PubMed     Abstract available

  209. AMER RG, Ezz El Arab LR, Abd El Ghany D, Saad AS, et al
    Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM).
    J Neurooncol. 2022 Jun 6. pii: 10.1007/s11060-022-04030.
    PubMed     Abstract available

  210. BERGER A, Bernstein K, Alzate JD, Mullen R, et al
    Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
    J Neurooncol. 2022 Jun 4. pii: 10.1007/s11060-022-04036.
    PubMed     Abstract available

  211. CHEN ZH, Zhang XH, Lin FH, Li C, et al
    The application of fluorescein sodium for the resection of medulloblastoma.
    J Neurooncol. 2022 Jun 3. pii: 10.1007/s11060-022-04035.
    PubMed     Abstract available

  212. SHAH HA, Mishra A, Gouzoulis MJ, Ben-Shalom N, et al
    Analysis of factors leading to early termination in glioblastoma-related clinical trials.
    J Neurooncol. 2022 Jun 1. pii: 10.1007/s11060-022-04039.
    PubMed     Abstract available

  213. GOODMAN AL, Velazquez Vega JE, Glenn C, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Jun 1. pii: 10.1007/s11060-022-04005.
    PubMed     Abstract available

    May 2022
  214. LE A, Mohammadi H, Mohammed T, Burney H, et al
    Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    J Neurooncol. 2022 May 31. pii: 10.1007/s11060-022-04038.
    PubMed     Abstract available

  215. OBERHEIM-BUSH NA, Shi W, McDermott MW, Grote A, et al
    The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
    J Neurooncol. 2022 May 31. pii: 10.1007/s11060-022-04033.
    PubMed     Abstract available

  216. PEREIRA ELR, Feio DCA, Tavares JPL, Morikawa NM, et al
    Uptake of lipid core nanoparticles by fragments of tissues collected during cerebral tumor excision surgeries: hypotheses for use in drug targeting therapy.
    J Neurooncol. 2022 May 25. pii: 10.1007/s11060-022-04028.
    PubMed     Abstract available

  217. REN L, Hua L, Bao Z, Deng J, et al
    Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.
    J Neurooncol. 2022 May 25. pii: 10.1007/s11060-022-04034.
    PubMed     Abstract available

  218. VUONG HG, Ngo TNM, Le HT, Dunn IF, et al
    The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    J Neurooncol. 2022 May 23. pii: 10.1007/s11060-022-04027.
    PubMed     Abstract available

  219. DADEY DYA, Rodrigues A, Haider G, Pollom EL, et al
    Impact of socio-economic factors on radiation treatment after resection of metastatic brain tumors: trends from a private insurance database.
    J Neurooncol. 2022 May 21. pii: 10.1007/s11060-022-04031.
    PubMed     Abstract available

  220. BREEN WG, Youland RS, Giri S, Jacobson SB, et al
    Initial results of a phase II trial of (18)F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.
    J Neurooncol. 2022 May 18. pii: 10.1007/s11060-022-04011.
    PubMed     Abstract available

  221. STRONG MJ, Koduri S, Allison JA, Pesavento CM, et al
    Bone metastasis from glioblastoma: a systematic review.
    J Neurooncol. 2022 May 17. pii: 10.1007/s11060-022-04025.
    PubMed     Abstract available

  222. LOPEZ-PEREZ CA, Franco-Mojica X, Villanueva-Gaona R, Diaz-Alba A, et al
    Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    J Neurooncol. 2022 May 14. pii: 10.1007/s11060-022-04024.
    PubMed     Abstract available

  223. RAMMOHAN N, Ho A, Saxena M, Bajaj A, et al
    Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.
    J Neurooncol. 2022 May 7. pii: 10.1007/s11060-022-04018.
    PubMed     Abstract available

  224. SHAO N, Mao J, Xue L, Wang R, et al
    Correction to: Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
    J Neurooncol. 2022 May 4. pii: 10.1007/s11060-022-04006.

  225. RIVERA PERLA KM, Tang OY, Durfey SNM, Vivas-Buitrago T, et al
    Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).
    J Neurooncol. 2022 May 3. pii: 10.1007/s11060-022-04020.
    PubMed     Abstract available

  226. MCTHENIA SS, Pandit-Taskar N, Grkovski M, Donzelli MA, et al
    Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device.
    J Neurooncol. 2022;157:457-463.
    PubMed     Abstract available

  227. LIU KX, Shang HH, Cacciotti C, Everdell E, et al
    DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
    J Neurooncol. 2022;157:499-510.
    PubMed     Abstract available

  228. WICKENHAUSER ME, Khan RB, Raches D, Ashford JM, et al
    The posterior fossa syndrome questionnaire: using science to inform practice.
    J Neurooncol. 2022;157:465-473.
    PubMed     Abstract available

  229. LIU ZM, Han Z, Wang JM, Sun T, et al
    Treatment and outcome of pediatric intracranial ependymoma after first relapse.
    J Neurooncol. 2022;157:385-396.
    PubMed     Abstract available

  230. HERSH AM, Antar A, Pennington Z, Aygun N, et al
    Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas.
    J Neurooncol. 2022;158:117-127.
    PubMed     Abstract available

  231. KAVOURIDIS VK, Ligon KL, Wen PY, Iorgulescu JB, et al
    Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
    J Neurooncol. 2022;158:111-116.
    PubMed     Abstract available

  232. IRONSIDE N, Snyder H, Xu Z, Schlesinger D, et al
    Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas.
    J Neurooncol. 2022;158:41-50.
    PubMed     Abstract available

  233. DEATKINE AB, Abdelrashid M, Tucker Z, Mehta A, et al
    High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    J Neurooncol. 2022;158:33-40.
    PubMed     Abstract available

    April 2022
  234. PARK DY, Tom MC, Chen Y, Tewari S, et al
    Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
    J Neurooncol. 2022 Apr 29. pii: 10.1007/s11060-022-04019.
    PubMed     Abstract available

  235. ZEITLBERGER AM, Putora PM, Hofer S, Schucht P, et al
    Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
    J Neurooncol. 2022 Apr 29. pii: 10.1007/s11060-022-04022.
    PubMed     Abstract available

  236. CHANG L, Wang J, Zhou F, Wang D, et al
    Retraction Note to: LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1.
    J Neurooncol. 2022 Apr 28. pii: 10.1007/s11060-022-04023.

  237. KLINGENSCHMID J, Krigers A, Pinggera D, Kerschbaumer J, et al
    The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma.
    J Neurooncol. 2022 Apr 25. pii: 10.1007/s11060-022-04001.
    PubMed     Abstract available

  238. NEMATI H, Fakhre-Taha M, Javanmard AR, Jahanbakhshi A, et al
    LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.
    J Neurooncol. 2022 Apr 23. pii: 10.1007/s11060-022-03992.
    PubMed     Abstract available

  239. WALSH LE, Polacek LC, Panageas K, Reiner A, et al
    Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-04010.
    PubMed     Abstract available

  240. LOUGHAN AR, Willis KD, Braun SE, Rodin G, et al
    Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-03988.
    PubMed     Abstract available

  241. AOYAMA M, Masukawa K, Sugiyama I, Morita T, et al
    Comparison of the quality of death between primary malignant brain tumor patients and other cancer patients: results from a nationwide bereavement survey in Japan.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-04013.
    PubMed     Abstract available

  242. CAI Q, Wu Y, Wang S, Huang T, et al
    Preoperative antiepileptic drug prophylaxis for early postoperative seizures in supratentorial meningioma: a single-center experience.
    J Neurooncol. 2022 Apr 17. pii: 10.1007/s11060-022-04009.
    PubMed     Abstract available

  243. SINGH DK, Shivalingappa PKM, Sharma A, Mondal A, et al
    NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.
    J Neurooncol. 2022 Apr 17. pii: 10.1007/s11060-022-04002.
    PubMed     Abstract available

  244. KERSCHBAUMER J, Krigers A, Demetz M, Pinggera D, et al
    The Clinical Frailty Scale as useful tool in patients with brain metastases.
    J Neurooncol. 2022 Apr 13. pii: 10.1007/s11060-022-04008.
    PubMed     Abstract available

  245. HOSOYA T, Takahashi M, Honda-Kitahara M, Miyakita Y, et al
    MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas.
    J Neurooncol. 2022 Apr 10. pii: 10.1007/s11060-022-03999.
    PubMed     Abstract available

  246. HALKETT GKB, Berg MN, Daudu D, Dhillon HM, et al
    Supportive care of patients diagnosed with high grade glioma and their carers in Australia.
    J Neurooncol. 2022 Apr 9. pii: 10.1007/s11060-022-03991.
    PubMed     Abstract available

  247. MO F, Meletti S, Belcastro V, Quadri S, et al
    Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
    J Neurooncol. 2022 Apr 9. pii: 10.1007/s11060-022-03998.
    PubMed     Abstract available

  248. LOUGHAN AR, Reid M, Willis KD, Davies A, et al
    The burden of a brain tumor: guiding patient centric care in neuro-oncology.
    J Neurooncol. 2022 Apr 8. pii: 10.1007/s11060-022-03993.
    PubMed     Abstract available

  249. STOYANOV GS, Lyutfi E, Georgieva R, Georgiev R, et al
    Diaph3 underlines tumor cell heterogeneity in glioblastoma with implications for treatment modalities resistance.
    J Neurooncol. 2022 Apr 5. pii: 10.1007/s11060-022-03996.
    PubMed     Abstract available

    Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study".
    J Neurooncol. 2022 Apr 5. pii: 10.1007/s11060-022-04000.

  251. MARCHETTI M, Pinzi V, Iezzoni C, Morlino S, et al
    Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.
    J Neurooncol. 2022 Apr 4. pii: 10.1007/s11060-022-03978.
    PubMed     Abstract available

  252. MESNY E, Barritault M, Izquierdo C, Poncet D, et al
    Gyriform infiltration as imaging biomarker for molecular glioblastomas.
    J Neurooncol. 2022 Apr 1. pii: 10.1007/s11060-022-03995.
    PubMed     Abstract available

  253. GIANTINI-LARSEN AM, Garton ALA, Villamater FN, Kuzan-Fischer CM, et al
    Familial colloid cysts: not a chance occurrence.
    J Neurooncol. 2022;157:321-332.
    PubMed     Abstract available

  254. KIM C, Lim M, Woodworth GF, Arvanitis CD, et al
    The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors.
    J Neurooncol. 2022;157:221-236.
    PubMed     Abstract available

  255. HART M, Anderson-Mellies A, Beltrami A, Gilani A, et al
    Population-based analysis of CNS tumor diagnoses, treatment, and survival in congenital and infant age groups.
    J Neurooncol. 2022;157:333-344.
    PubMed     Abstract available

  256. METZGER S, Weiser A, Gerber NU, Otth M, et al
    Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes.
    J Neurooncol. 2022;157:307-317.
    PubMed     Abstract available

    March 2022
  257. BERTHOLD D, Carrasco AP, Uhl E, Muller H, et al
    Palliative care of older glioblastoma patients in neurosurgery.
    J Neurooncol. 2022 Mar 24. pii: 10.1007/s11060-022-03985.
    PubMed     Abstract available

  258. WEI Z, Niranjan A, Abou-Al-Shaar H, Deng H, et al
    A volume matched comparison of survival after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases.
    J Neurooncol. 2022 Mar 22. pii: 10.1007/s11060-022-03981.
    PubMed     Abstract available

  259. GRITSCH D, Castro LNG
    Relevant pharmacologic interactions in the concurrent management of brain tumor-related epilepsy and venous thromboembolism: a systematic review.
    J Neurooncol. 2022 Mar 21. pii: 10.1007/s11060-022-03984.
    PubMed     Abstract available

  260. NIDAMANURI P, Drappatz J
    Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
    J Neurooncol. 2022 Mar 17. pii: 10.1007/s11060-022-03979.
    PubMed     Abstract available

  261. BIN ALAMER O, Palmisciano P, Mallela AN, Labib MA, et al
    Stereotactic radiosurgery in the management of petroclival meningiomas: a systematic review and meta-analysis of treatment outcomes of primary and adjuvant radiosurgery.
    J Neurooncol. 2022 Mar 17. pii: 10.1007/s11060-021-03934.
    PubMed     Abstract available

  262. RUTENBERG MS, Holtzman AL, Indelicato DJ, Huh S, et al
    Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series.
    J Neurooncol. 2022 Mar 12. pii: 10.1007/s11060-022-03983.
    PubMed     Abstract available

  263. VANHAUWAERT D, Pinson H, Sweldens C, Du Four S, et al
    Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey.
    J Neurooncol. 2022 Mar 11. pii: 10.1007/s11060-022-03971.
    PubMed     Abstract available

  264. MOON HH, Park JE, Kim YH, Kim JH, et al
    Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
    J Neurooncol. 2022 Mar 11. pii: 10.1007/s11060-022-03980.
    PubMed     Abstract available

  265. ROBERTS JW, Powlovich L, Sheybani N, LeBlang S, et al
    Focused ultrasound for the treatment of glioblastoma.
    J Neurooncol. 2022 Mar 10. pii: 10.1007/s11060-022-03974.
    PubMed     Abstract available

  266. BARRAGAN-PEREZ EJ, Alvarez-Amado DE, Dies-Suarez P, Tobon SH, et al
    Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience.
    J Neurooncol. 2022 Mar 10. pii: 10.1007/s11060-022-03972.
    PubMed     Abstract available

  267. MILLS MN, King W, Soyano A, Pina Y, et al
    Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
    J Neurooncol. 2022 Mar 4. pii: 10.1007/s11060-022-03977.
    PubMed     Abstract available

  268. PATRICK HH, Sherman JH, Elder JB, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Mar 4. pii: 10.1007/s11060-021-03881.
    PubMed     Abstract available

  269. DE MARCELLUS C, Tauziede-Espariat A, Cuinet A, Pasqualini C, et al
    The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
    J Neurooncol. 2022 Mar 3. pii: 10.1007/s11060-022-03970.
    PubMed     Abstract available

  270. BROGGI G, Gianno F, Shemy DT, Massimino M, et al
    Atypical teratoid/rhabdoid tumor in adults: a systematic review of the literature with meta-analysis and additional reports of 4 cases.
    J Neurooncol. 2022;157:1-14.
    PubMed     Abstract available

  271. DIAZ M, Singh P, Kotchetkov IS, Skakodub A, et al
    Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases.
    J Neurooncol. 2022;157:81-90.
    PubMed     Abstract available

  272. PECIU-FLORIANU I, Legrand V, Monfilliette-Djelad A, Maurage CA, et al
    Frameless robot-assisted stereotactic biopsies for lesions of the brainstem-a series of 103 consecutive biopsies.
    J Neurooncol. 2022;157:109-119.
    PubMed     Abstract available

    February 2022
  273. GROGAN D, Bray DP, Cosgrove M, Boucher A, et al
    Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
    J Neurooncol. 2022 Feb 25. pii: 10.1007/s11060-022-03961.
    PubMed     Abstract available

  274. BYRNE E, Abel S, Yu A, Shepard M, et al
    Trends in radiation dose for low grade gliomas across the United States.
    J Neurooncol. 2022 Feb 23. pii: 10.1007/s11060-022-03962.
    PubMed     Abstract available

  275. GERMANO IM, Ziu M, Wen P, Ormond DR, et al
    Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Feb 23. pii: 10.1007/s11060-021-03900.
    PubMed     Abstract available

  276. VALLEJO FA, Eichberg DG, Morell AA, Shah AH, et al
    Same-day discharge after brain tumor resection: a prospective pilot study.
    J Neurooncol. 2022 Feb 22. pii: 10.1007/s11060-022-03969.
    PubMed     Abstract available

  277. OBRECHT D, Mynarek M, Hagel C, Kwiecien R, et al
    Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.
    J Neurooncol. 2022 Feb 21. pii: 10.1007/s11060-021-03913.
    PubMed     Abstract available

  278. LIN R, Xu Y, Xie S, Zhang Y, et al
    Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    J Neurooncol. 2022 Feb 21. pii: 10.1007/s11060-022-03964.
    PubMed     Abstract available

  279. RAMOS-FRESNEDO A, Pullen MW, Perez-Vega C, Domingo RA, et al
    The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
    J Neurooncol. 2022 Feb 17. pii: 10.1007/s11060-022-03960.
    PubMed     Abstract available

  280. MORENO DA, da Silva LS, Zanon MF, Bonatelli M, et al
    Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
    J Neurooncol. 2022 Feb 15. pii: 10.1007/s11060-022-03965.
    PubMed     Abstract available

  281. ABDULHALEEM M, Johnston H, D'Agostino R Jr, Lanier C, et al
    Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases.
    J Neurooncol. 2022 Feb 15. pii: 10.1007/s11060-022-03951.
    PubMed     Abstract available

  282. SOLANO-PAEZ P, Fonseca A, Baroni LV, Amayiri N, et al
    Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites.
    J Neurooncol. 2022 Feb 5. pii: 10.1007/s11060-022-03956.
    PubMed     Abstract available

  283. HAIM O, Abramov S, Shofty B, Fanizzi C, et al
    Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.
    J Neurooncol. 2022 Feb 4. pii: 10.1007/s11060-022-03946.
    PubMed     Abstract available

  284. FATIMA N, Maxwell AK, La Dine A, Barnard ZR, et al
    Predictors of hearing functional outcome following surgery for cerebellopontine angle meningioma.
    J Neurooncol. 2022 Feb 3. pii: 10.1007/s11060-022-03958.
    PubMed     Abstract available

  285. HAQUE W, Teh C, Butler EB, Teh BS, et al
    Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    J Neurooncol. 2022 Feb 1. pii: 10.1007/s11060-022-03955.
    PubMed     Abstract available

  286. SHEPARD MJ, Haider AS, Prabhu SS, Sawaya R, et al
    Long term outcomes following surgery for pineal region tumors.
    J Neurooncol. 2022;156:491-498.
    PubMed     Abstract available

  287. LUKAS RV, Thakkar JP, Cristofanilli M, Chandra S, et al
    Leptomeningeal metastases: the future is now.
    J Neurooncol. 2022;156:443-452.
    PubMed     Abstract available

  288. WOLFF JE, Van Gool SW, Kutluk T, Diez B, et al
    Final results of the Choroid Plexus Tumor study CPT-SIOP-2000.
    J Neurooncol. 2022;156:599-613.
    PubMed     Abstract available

    January 2022
  289. LEE YP, Jung HA, Lee MS, Choi JW, et al
    Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
    J Neurooncol. 2022 Jan 30. pii: 10.1007/s11060-021-03930.
    PubMed     Abstract available

  290. YANG K, Landry AP, Aljoghaiman M, Gutierrez E, et al
    Postoperative CT scans after resection of brain metastases: neurosurgical routine or added value?
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03957.
    PubMed     Abstract available

  291. CHIANG JA, Feghali PT, Saavedra A, Whitaker AM, et al
    Effects of sleep disturbance on neuropsychological functioning in patients with pediatric brain tumor.
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03954.
    PubMed     Abstract available

  292. PIKIS S, Mantziaris G, Islim AI, Peker S, et al
    Stereotactic radiosurgery versus active surveillance for incidental, convexity meningiomas: a matched cohort analysis from the IMPASSE study.
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03953.
    PubMed     Abstract available

  293. MARKU M, Rasmussen BK, Belmonte F, Andersen EAW, et al
    Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018.
    J Neurooncol. 2022 Jan 28. pii: 10.1007/s11060-022-03948.
    PubMed     Abstract available

  294. NETH BJ, Balakrishnan SN, Carabenciov ID, Uhm JH, et al
    Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    J Neurooncol. 2022 Jan 25. pii: 10.1007/s11060-022-03950.
    PubMed     Abstract available

  295. GERRITSEN JKW, Broekman MLD, De Vleeschouwer S, Schucht P, et al
    Decision making and surgical modality selection in glioblastoma patients: an international multicenter survey.
    J Neurooncol. 2022 Jan 24. pii: 10.1007/s11060-021-03894.
    PubMed     Abstract available

  296. MANTZIARIS G, Pikis S, Samanci Y, Peker S, et al
    Stereotactic radiosurgery versus active surveillance for asymptomatic, skull-based meningiomas: an international, multicenter matched cohort study.
    J Neurooncol. 2022 Jan 24. pii: 10.1007/s11060-021-03923.
    PubMed     Abstract available

  297. NORONHA C, Ribeiro AS, Taipa R, Leitao D, et al
    PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.
    J Neurooncol. 2022 Jan 23. pii: 10.1007/s11060-021-03907.
    PubMed     Abstract available

  298. PARK DY, Tom MC, Wei W, Tewari S, et al
    Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
    J Neurooncol. 2022 Jan 22. pii: 10.1007/s11060-021-03920.
    PubMed     Abstract available

  299. NAZEM A, Guiry SC, Pourfathi M, Ware JB, et al
    MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma.
    J Neurooncol. 2022 Jan 19. pii: 10.1007/s11060-022-03947.
    PubMed     Abstract available

  300. MOITRA P, Chatterjee A, Kota PK, Epari S, et al
    Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
    J Neurooncol. 2022 Jan 17. pii: 10.1007/s11060-022-03944.
    PubMed     Abstract available

  301. LAMBA N, Groves A, Torre M, Yeo KK, et al
    The epidemiology of primary and metastatic brain tumors in infancy through childhood.
    J Neurooncol. 2022 Jan 17. pii: 10.1007/s11060-021-03927.
    PubMed     Abstract available

  302. DADARIO NB, Zaman A, Pandya M, Dlouhy BJ, et al
    Endoscopic-assisted surgical approach for butterfly glioma surgery.
    J Neurooncol. 2022 Jan 15. pii: 10.1007/s11060-022-03945.
    PubMed     Abstract available

  303. TANG OY, Clarke RA, Rivera Perla KM, Corcoran Ruiz KM, et al
    Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis.
    J Neurooncol. 2022 Jan 13. pii: 10.1007/s11060-021-03922.
    PubMed     Abstract available

  304. AFTAB K, Aamir FB, Mallick S, Mubarak F, et al
    Radiomics for precision medicine in glioblastoma.
    J Neurooncol. 2022 Jan 12. pii: 10.1007/s11060-021-03933.
    PubMed     Abstract available

  305. MASSARWEH A, Tschernichovsky R, Stemmer A, Benouaich-Amiel A, et al
    Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.
    J Neurooncol. 2022 Jan 12. pii: 10.1007/s11060-021-03911.
    PubMed     Abstract available

  306. PERLOW HK, Yaney A, Yang M, Klamer B, et al
    Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
    J Neurooncol. 2022 Jan 11. pii: 10.1007/s11060-021-03925.
    PubMed     Abstract available

  307. PENA PINO I, Ma J, Hori YS, Fomchenko E, et al
    Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience.
    J Neurooncol. 2022 Jan 10. pii: 10.1007/s11060-021-03893.
    PubMed     Abstract available

  308. DONO A, Zhu P, Holmes E, Takayasu T, et al
    Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.
    J Neurooncol. 2022 Jan 8. pii: 10.1007/s11060-021-03917.
    PubMed     Abstract available

  309. KILIAN A, Aigner A, Simon M, Salchow DJ, et al
    Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
    J Neurooncol. 2022 Jan 7. pii: 10.1007/s11060-021-03941.
    PubMed     Abstract available

  310. GRIMALDI S, Harlay V, Appay R, Bequet C, et al
    Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
    J Neurooncol. 2022 Jan 7. pii: 10.1007/s11060-022-03943.
    PubMed     Abstract available

  311. EATZ TA, Eichberg DG, Lu VM, Di L, et al
    Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.
    J Neurooncol. 2022 Jan 6. pii: 10.1007/s11060-021-03901.
    PubMed     Abstract available

  312. KAWAUCHI D, Ohno M, Honda-Kitahara M, Miyakita Y, et al
    The clinical characteristics and outcomes of incidentally discovered glioblastoma.
    J Neurooncol. 2022 Jan 5. pii: 10.1007/s11060-021-03931.
    PubMed     Abstract available

  313. MAGANA SM, Peterson TE, Evans JE, Decker PA, et al
    Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles.
    J Neurooncol. 2022 Jan 5. pii: 10.1007/s11060-021-03914.
    PubMed     Abstract available

  314. CHEN JS, Clarke R, Haddad AF, Wang EJ, et al
    The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.
    J Neurooncol. 2022 Jan 4. pii: 10.1007/s11060-021-03940.
    PubMed     Abstract available

  315. GERAGHTY BJ, Dasgupta A, Sandhu M, Malik N, et al
    Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes.
    J Neurooncol. 2022 Jan 3. pii: 10.1007/s11060-021-03939.
    PubMed     Abstract available

  316. ZUO J, Liu C, Ni H, Yu Z, et al
    WDR34 affects PI3K/Akt and Wnt/beta-catenin pathways to regulates malignant biological behaviors of glioma cells.
    J Neurooncol. 2022 Jan 3. pii: 10.1007/s11060-021-03932.
    PubMed     Abstract available

  317. KIM N, Lim DH, Yoon SE, Kim SJ, et al
    Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.
    J Neurooncol. 2022;156:307-316.
    PubMed     Abstract available

  318. LOIZIDOU M, Sefcikova V, Ekert JO, Bone M, et al
    Reforming support systems of newly diagnosed brain cancer patients: a systematic review.
    J Neurooncol. 2022;156:61-71.
    PubMed     Abstract available

  319. NAKAJIMA R, Kinoshita M, Okita H, Nakada M, et al
    Quality of life following awake surgery depends on ability of executive function, verbal fluency, and movement.
    J Neurooncol. 2022;156:173-183.
    PubMed     Abstract available

    December 2021
  320. ROBERT SM, Vetsa S, Nadar A, Vasandani S, et al
    Correction to: The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
    J Neurooncol. 2021 Dec 30. pii: 10.1007/s11060-021-03937.

  321. KLEMENT RJ, Popp I, Kaul D, Ehret F, et al
    Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
    J Neurooncol. 2021 Dec 23. pii: 10.1007/s11060-021-03926.
    PubMed     Abstract available

  322. TESKE N, Karschnia P, Weller J, Siller S, et al
    Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    J Neurooncol. 2021 Dec 13. pii: 10.1007/s11060-021-03912.
    PubMed     Abstract available

  323. JIMENEZ AE, Khalafallah AM, Botros D, Horowitz MA, et al
    The role of anticoagulation for superior sagittal sinus thrombosis following craniotomy for resection of parasagittal/parafalcine meningiomas.
    J Neurooncol. 2021 Dec 2. pii: 10.1007/s11060-021-03916.
    PubMed     Abstract available

  324. JOHNSON KJ, Wang X, Barnes JM, Delavar A, et al
    Residential distance from the reporting hospital and survival among adolescents, and young adults diagnosed with CNS tumors.
    J Neurooncol. 2021;155:353-361.
    PubMed     Abstract available

  325. HAINC N, Alsafwani N, Gao A, O'Halloran PJ, et al
    The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery.
    J Neurooncol. 2021;155:325-333.
    PubMed     Abstract available

    November 2021
  326. ROBERT SM, Vetsa S, Nadar A, Vasandani S, et al
    The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
    J Neurooncol. 2021 Nov 30. pii: 10.1007/s11060-021-03874.
    PubMed     Abstract available

  327. YOUNG M, Delaney A, Jurbergs N, Pan H, et al
    Radiotherapy alone for pediatric patients with craniopharyngioma.
    J Neurooncol. 2021 Nov 30. pii: 10.1007/s11060-021-03908.
    PubMed     Abstract available

  328. SOLER DC, Kerstetter-Fogle A, McCormick TS, Sloan AE, et al
    Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    J Neurooncol. 2021 Nov 26. pii: 10.1007/s11060-021-03902.
    PubMed     Abstract available

  329. GARCIA CR, Myint ZW, Jayswal R, Wang C, et al
    Hematological adverse events in the management of glioblastoma.
    J Neurooncol. 2021 Nov 24. pii: 10.1007/s11060-021-03891.
    PubMed     Abstract available

  330. WEFEL JS, Zhou R, Sulman EP, Boehling NS, et al
    Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients.
    J Neurooncol. 2021 Nov 24. pii: 10.1007/s11060-021-03905.
    PubMed     Abstract available

  331. BARAK T, Vetsa S, Nadar A, Jin L, et al
    Correction to: Surgical strategies for older patients with glioblastoma.
    J Neurooncol. 2021 Nov 23. pii: 10.1007/s11060-021-03888.

  332. ROH TH, Lee JH, Kim SJ, Shim JK, et al
    A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03903.
    PubMed     Abstract available

  333. YUSUF M, Rattani A, Gaskins J, Oliver AL, et al
    Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03899.
    PubMed     Abstract available

  334. HENDERSON F JR, Schwartz TH
    Update on management of craniopharyngiomas.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03906.
    PubMed     Abstract available

  335. BEHLING F, Fodi C, Wang S, Hempel JM, et al
    Increased proliferation is associated with CNS invasion in meningiomas.
    J Neurooncol. 2021 Nov 20. pii: 10.1007/s11060-021-03892.
    PubMed     Abstract available

  336. PAOLI C, Segard S, Burel-Vandenbos F
    Is H3 K27M mutation testing relevant in the diagnostic routine of WHO grade 4 gliomas exclusively located in the corpus callosum in adults?
    J Neurooncol. 2021 Nov 20. pii: 10.1007/s11060-021-03884.

  337. BUNEVICIUS A, Pikis S, Kondziolka D, Patel DN, et al
    Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03883.
    PubMed     Abstract available

  338. PALMISCIANO P, El Ahmadieh TY, Haider AS, Bin Alamer O, et al
    Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03898.
    PubMed     Abstract available

  339. YANG K, Luan L, Li X, Sun X, et al
    ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03896.
    PubMed     Abstract available

  340. VUONG HG, Le HT, Ngo TNM, Fung KM, et al
    H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
    J Neurooncol. 2021 Nov 18. pii: 10.1007/s11060-021-03890.
    PubMed     Abstract available

  341. SARAN F, Welsh L, James A, McBain C, et al
    Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
    J Neurooncol. 2021 Nov 17. pii: 10.1007/s11060-021-03877.
    PubMed     Abstract available

  342. PATIL N, Somasundaram E, Waite KA, Lathia JD, et al
    Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    J Neurooncol. 2021 Nov 10. pii: 10.1007/s11060-021-03886.
    PubMed     Abstract available

  343. ZIU M, Goyal S, Olson JJ
    Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.
    J Neurooncol. 2021 Nov 8. pii: 10.1007/s11060-021-03857.
    PubMed     Abstract available

  344. SHEYBANI ND, Witter AR, Garrison WJ, Miller GW, et al
    Profiling of the immune landscape in murine glioblastoma following blood brain/tumor barrier disruption with MR image-guided focused ultrasound.
    J Neurooncol. 2021 Nov 3. pii: 10.1007/s11060-021-03887.
    PubMed     Abstract available

  345. YOULDEN DR, Henshaw C, Gottardo NG, Hassall T, et al
    Incidence and survival for childhood central nervous system tumours in Australia, 1983-2016.
    J Neurooncol. 2021;155:203-213.
    PubMed     Abstract available

  346. ADOLPH JE, Fleischhack G, Gaab C, Mikasch R, et al
    Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.
    J Neurooncol. 2021;155:193-202.
    PubMed     Abstract available

  347. WANG S, Sun MZ, Abecassis IJ, Weil AG, et al
    Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma-and individual participant data meta-analysis (IPDMA).
    J Neurooncol. 2021;155:155-163.
    PubMed     Abstract available

  348. LU VM, Luther EM, Eichberg DG, Morell AA, et al
    Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade.
    J Neurooncol. 2021;155:165-172.
    PubMed     Abstract available

    October 2021
  349. KANAZAWA T, Ohara K, Kitamura Y, Nakaya M, et al
    Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy.
    J Neurooncol. 2021 Oct 31. pii: 10.1007/s11060-021-03855.
    PubMed     Abstract available

  350. JAMAN E, Zhang X, Sandlesh P, Habib A, et al
    History of atopy confers improved outcomes in IDH mutant and wildtype lower grade gliomas.
    J Neurooncol. 2021 Oct 29. pii: 10.1007/s11060-021-03854.
    PubMed     Abstract available

  351. HASEGAWA H, Vakharia K, Link MJ, Stafford SL, et al
    The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience.
    J Neurooncol. 2021 Oct 27. pii: 10.1007/s11060-021-03882.
    PubMed     Abstract available

  352. WINOGRAD E, Germano I, Wen P, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03876.
    PubMed     Abstract available

  353. OLSON JJ
    Congress of neurological surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03850.
    PubMed     Abstract available

  354. JOHNSON DR, Glenn CA, Javan R, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03853.
    PubMed     Abstract available

  355. MALIK N, Geraghty B, Dasgupta A, Maralani PJ, et al
    MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03866.
    PubMed     Abstract available

  356. DIXIT KS, Sachdev S, Amidei C, Kumthekar P, et al
    A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    J Neurooncol. 2021 Oct 24. pii: 10.1007/s11060-021-03875.
    PubMed     Abstract available

  357. GIRARD A, Le Reste PJ, Metais A, Carsin Nicol B, et al
    Combining (18)F-DOPA PET and MRI with perfusion-weighted imaging improves delineation of high-grade subregions in enhancing and non-enhancing gliomas prior treatment: a biopsy-controlled study.
    J Neurooncol. 2021 Oct 22. pii: 10.1007/s11060-021-03873.
    PubMed     Abstract available

  358. SAMANIC CM, Teer JK, Thompson ZJ, Creed JH, et al
    Mitochondrial DNA sequence variation and risk of meningioma.
    J Neurooncol. 2021 Oct 20. pii: 10.1007/s11060-021-03878.
    PubMed     Abstract available

  359. WILCOX JA, Brown S, Reiner AS, Young RJ, et al
    Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation.
    J Neurooncol. 2021 Oct 16. pii: 10.1007/s11060-021-03872.
    PubMed     Abstract available

  360. YERRABOTHALA S, Gourley BL, Ford JC, Ahmed SR, et al
    Systemic coagulation is activated in patients with meningioma and glioblastoma.
    J Neurooncol. 2021 Oct 15. pii: 10.1007/s11060-021-03865.
    PubMed     Abstract available

  361. SOHN B, An C, Kim D, Ahn SS, et al
    Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
    J Neurooncol. 2021 Oct 14. pii: 10.1007/s11060-021-03870.
    PubMed     Abstract available

  362. FANG S, Liang Y, Li L, Wang L, et al
    Correction to: Tumor location-based classification of surgery-related language impairments in patients with glioma.
    J Neurooncol. 2021 Oct 12. pii: 10.1007/s11060-021-03871.

  363. BARAK T, Vetsa S, Nadar A, Jin L, et al
    Surgical strategies for older patients with glioblastoma.
    J Neurooncol. 2021 Oct 9. pii: 10.1007/s11060-021-03862.
    PubMed     Abstract available

  364. AKMAL S, Ginalis EE, Patel NV, Aiken R, et al
    Leptomeningeal disease in glioblastoma: endgame or opportunity?
    J Neurooncol. 2021 Oct 8. pii: 10.1007/s11060-021-03864.
    PubMed     Abstract available

  365. RINCON-TORROELLA J, Khela H, Bettegowda A, Bettegowda C, et al
    Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients.
    J Neurooncol. 2021 Oct 6. pii: 10.1007/s11060-021-03837.
    PubMed     Abstract available

  366. PATEL NV, Wong T, Fralin SR, Li M, et al
    Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
    J Neurooncol. 2021 Oct 3. pii: 10.1007/s11060-021-03851.
    PubMed     Abstract available

  367. ALDRICH KD, Horne VE, Bielamowicz K, Sonabend RY, et al
    Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03847.
    PubMed     Abstract available

  368. FANG S, Liang Y, Li L, Wang L, et al
    Tumor location-based classification of surgery-related language impairments in patients with glioma.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03858.
    PubMed     Abstract available

  369. ORT J, Hamou HA, Kernbach JM, Hakvoort K, et al
    (18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03844.
    PubMed     Abstract available

  370. CABRAL DE CARVALHO CORREA D, Tesser-Gamba F, Dias Oliveira I, Saba da Silva N, et al
    Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
    J Neurooncol. 2021;155:13-23.
    PubMed     Abstract available

  371. BROWNE-FARMER C, Hazrati LN, Mamatjan Y, Zadeh G, et al
    Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?
    J Neurooncol. 2021;155:63-70.
    PubMed     Abstract available

    September 2021
  372. FUJITA Y, Nagashima H, Tanaka K, Hashiguchi M, et al
    Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas.
    J Neurooncol. 2021 Sep 22. pii: 10.1007/s11060-021-03845.
    PubMed     Abstract available

  373. CACHO-DIAZ B, Cuapatencatl LD, Rodriguez JA, Garcilazo-Reyes YJ, et al
    Identification of a high-risk group for brain metastases in non-small cell lung cancer patients.
    J Neurooncol. 2021 Sep 21. pii: 10.1007/s11060-021-03849.
    PubMed     Abstract available

  374. ROGERS S, Stauffer A, Lomax N, Alonso S, et al
    Five fraction stereotactic radiotherapy after brain metastasectomy: a single-institution experience and literature review.
    J Neurooncol. 2021 Sep 21. pii: 10.1007/s11060-021-03840.
    PubMed     Abstract available

  375. CARDONA AF, Jaramillo-Velasquez D, Ruiz-Patino A, Polo C, et al
    Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
    J Neurooncol. 2021 Sep 9. pii: 10.1007/s11060-021-03834.
    PubMed     Abstract available

  376. BARONI LV, Freytes C, Fernandez Ponce N, Oller A, et al
    Craniospinal irradiation as part of re-irradiation for children with recurrent medulloblastoma.
    J Neurooncol. 2021 Sep 9. pii: 10.1007/s11060-021-03842.
    PubMed     Abstract available

  377. DICPINIGAITIS AJ, Kazim SF, Schmidt MH, Couldwell WT, et al
    Association of baseline frailty status and age with postoperative morbidity and mortality following intracranial meningioma resection.
    J Neurooncol. 2021 Sep 8. pii: 10.1007/s11060-021-03841.
    PubMed     Abstract available

  378. BRAUN SE, Aslanzadeh FJ, Lanoye A, Fountain-Zaragoza S, et al
    Working memory training for adult glioma patients: a proof-of-concept study.
    J Neurooncol. 2021 Sep 7. pii: 10.1007/s11060-021-03839.
    PubMed     Abstract available

  379. VAN DER LINDEN SD, Rutten GM, Dirven L, Taphoorn MJB, et al
    eHealth cognitive rehabilitation for brain tumor patients: results of a randomized controlled trial.
    J Neurooncol. 2021 Sep 6. pii: 10.1007/s11060-021-03828.
    PubMed     Abstract available

  380. PENG G, Su J, Xiao S, Liu Q, et al
    LINC00152 acts as a potential marker in gliomas and promotes tumor proliferation and invasion through the LINC00152/miR-107/RAB10 axis.
    J Neurooncol. 2021 Sep 3. pii: 10.1007/s11060-021-03836.
    PubMed     Abstract available

  381. LUO T, Ding K, Ji J, Zhang X, et al
    Cytoskeleton-associated protein 4 (CKAP4) promotes malignant progression of human gliomas through inhibition of the Hippo signaling pathway.
    J Neurooncol. 2021 Sep 2. pii: 10.1007/s11060-021-03831.
    PubMed     Abstract available

  382. AHMETI H, Borzikowsky C, Hollander D, Rocken C, et al
    Risks and neurological benefits of meningioma surgery in elderly patients compared to young patients.
    J Neurooncol. 2021 Sep 1. pii: 10.1007/s11060-021-03832.
    PubMed     Abstract available

  383. NORMAN S, Ramos A, Giantini Larsen AM, Bander E, et al
    Impact of the COVID-19 pandemic on neuro-oncology outcomes.
    J Neurooncol. 2021;154:375-381.
    PubMed     Abstract available

  384. HUNTOON K, Makary MS, Damante M, Giglio P, et al
    Intraoperative 3 T MRI is more correlative to residual disease extent than early postoperative MRI.
    J Neurooncol. 2021;154:345-351.
    PubMed     Abstract available

  385. BANDER ED, Yuan M, Reiner AS, Garton ALA, et al
    Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.
    J Neurooncol. 2021;154:301-313.
    PubMed     Abstract available

  386. TANAKA R, Inoue K, Yamada Y, Yoshida M, et al
    A case of primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion and systematic meta-review.
    J Neurooncol. 2021;154:247-256.
    PubMed     Abstract available

  387. SANDHU MRS, Chiang VL, Tran T, Yu JB, et al
    Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.
    J Neurooncol. 2021;154:197-203.
    PubMed     Abstract available

  388. KIM N, Lim DH, Yoon SE, Kim SJ, et al
    Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    J Neurooncol. 2021;154:207-217.
    PubMed     Abstract available

  389. OTANI R, Mukasa A, Uzuka T, Higuchi F, et al
    Gene expression profiling of 19q-loss astrocytomas suggest a specific pattern associated with the better prognosis.
    J Neurooncol. 2021;154:221-228.
    PubMed     Abstract available

    August 2021
  390. PERAGALLO JH, Bruce BB, Vasseneix C, Jariyakosol S, et al
    Vision-related quality-of-life in pediatric primary brain tumor patients.
    J Neurooncol. 2021 Aug 30. pii: 10.1007/s11060-021-03835.
    PubMed     Abstract available

  391. NOFFSINGER B, Witter A, Sheybani N, Xiao A, et al
    Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner.
    J Neurooncol. 2021 Aug 25. pii: 10.1007/s11060-021-03822.
    PubMed     Abstract available

  392. SEARS TK, Horbinski CM, Woolard KD
    IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
    J Neurooncol. 2021 Aug 23. pii: 10.1007/s11060-021-03829.
    PubMed     Abstract available

  393. APRA C, Guillemot D, Frouin E, Bouvier C, et al
    Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.
    J Neurooncol. 2021 Aug 20. pii: 10.1007/s11060-021-03830.
    PubMed     Abstract available

  394. XIAO B, Lv SG, Wu MJ, Shen XL, et al
    Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.
    J Neurooncol. 2021 Aug 6. pii: 10.1007/s11060-021-03814.
    PubMed     Abstract available

  395. JIN L, Youngblood MW, Gupte TP, Vetsa S, et al
    Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas.
    J Neurooncol. 2021 Aug 4. pii: 10.1007/s11060-021-03819.
    PubMed     Abstract available

  396. SCHNEIDER M, Schafer N, Apallas S, Potthoff AL, et al
    Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma.
    J Neurooncol. 2021 Aug 4. pii: 10.1007/s11060-021-03817.
    PubMed     Abstract available

  397. TAKAMI H, Graffeo CS, Perry A, Ohno M, et al
    Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study.
    J Neurooncol. 2021;154:121-130.
    PubMed     Abstract available

  398. GAZZERI R, Telera S, Galarza M, Callovini GM, et al
    Surgical treatment of solitary intradural extramedullary spinal cord metastases from solid cancers of non-neurogenic origin. A multicenter study.
    J Neurooncol. 2021;154:101-112.
    PubMed     Abstract available

  399. DHAWAN S, Venteicher AS, Butler WE, Carter BS, et al
    Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis.
    J Neurooncol. 2021;154:1-11.
    PubMed     Abstract available

  400. ALEKSONIS HA, Krishnamurthy LC, King TZ
    White matter hyperintensity volumes are related to processing speed in long-term survivors of childhood cerebellar tumors.
    J Neurooncol. 2021;154:63-72.
    PubMed     Abstract available

  401. SAITO M, Wages NA, Schiff D
    Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma.
    J Neurooncol. 2021;154:41-47.
    PubMed     Abstract available

    July 2021
  402. TAKIGAWA K, Hata N, Michiwaki Y, Hiwatashi A, et al
    Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
    J Neurooncol. 2021 Jul 28. pii: 10.1007/s11060-021-03812.
    PubMed     Abstract available

  403. LIN MR, Chen PY, Wang HC, Lin PC, et al
    Prevalence of sleep disturbances and their effects on quality of life in adults with untreated pituitary tumor and meningioma.
    J Neurooncol. 2021 Jul 24. pii: 10.1007/s11060-021-03811.
    PubMed     Abstract available

  404. OGINO A, Niranjan A, Kano H, Flickinger JC, et al
    Optimizing stereotactic radiosurgery in patients with recurrent or residual craniopharyngiomas.
    J Neurooncol. 2021 Jul 20. pii: 10.1007/s11060-021-03806.
    PubMed     Abstract available

  405. LEE EJ, Choi KS, Park ES, Cho YH, et al
    Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review.
    J Neurooncol. 2021 Jul 15. pii: 10.1007/s11060-021-03805.
    PubMed     Abstract available

  406. BUNEVICIUS A, Pikis S, Padilla F, Prada F, et al
    Sonodynamic therapy for gliomas.
    J Neurooncol. 2021 Jul 12. pii: 10.1007/s11060-021-03807.
    PubMed     Abstract available

  407. PALMISCIANO P, Haider AS, Nwagwu CD, Wahood W, et al
    Bevacizumab vs laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: a systematic review and meta-analysis.
    J Neurooncol. 2021 Jul 3. pii: 10.1007/s11060-021-03802.
    PubMed     Abstract available

  408. LIU IC, Holtzman AL, Rotondo RL, Indelicato DJ, et al
    Correction to: Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
    J Neurooncol. 2021 Jul 1. pii: 10.1007/s11060-021-03798.

  409. VAN OPIJNEN MP, van der Meer PB, Dirven L, Fiocco M, et al
    The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.
    J Neurooncol. 2021 Jul 1. pii: 10.1007/s11060-021-03800.
    PubMed     Abstract available

  410. MEHTA GU, Barone AK, Bradford D, Larkins E, et al
    US Food and Drug Administration regulatory updates in neuro-oncology.
    J Neurooncol. 2021;153:375-381.
    PubMed     Abstract available

  411. BUSH NAO, Young JS, Zhang Y, Dalle Ore CL, et al
    A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.
    J Neurooncol. 2021;153:447-454.
    PubMed     Abstract available

  412. JOHNSON RA, Do TH, Palzer EF, Cramer SW, et al
    Pattern of technology diffusion in the adoption of stereotactic laser interstitial thermal therapy (LITT) in neuro-oncology.
    J Neurooncol. 2021;153:417-424.
    PubMed     Abstract available

    June 2021
  413. AHN SS, An C, Park YW, Han K, et al
    Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma.
    J Neurooncol. 2021 Jun 30. pii: 10.1007/s11060-021-03801.
    PubMed     Abstract available

  414. MAREIKE M, Franziska SB, Julia E, Daniel H, et al
    Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    J Neurooncol. 2021 Jun 29. pii: 10.1007/s11060-021-03794.
    PubMed     Abstract available

  415. VAN RUITENBEEK NJ, Ho VKY, Westgeest HM, Beerepoot LV, et al
    Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.
    J Neurooncol. 2021 Jun 25. pii: 10.1007/s11060-021-03793.
    PubMed     Abstract available

  416. PORPER K, Shpatz Y, Plotkin L, Pechthold RG, et al
    A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
    J Neurooncol. 2021 Jun 21. pii: 10.1007/s11060-021-03786.
    PubMed     Abstract available

  417. CHO A, Untersteiner H, Fitschek F, Khalaveh F, et al
    The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor.
    J Neurooncol. 2021 Jun 20. pii: 10.1007/s11060-021-03788.
    PubMed     Abstract available

  418. BETTAG C, Hussein A, Sachkova A, Bock HC, et al
    Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
    J Neurooncol. 2021 Jun 20. pii: 10.1007/s11060-021-03792.
    PubMed     Abstract available

  419. NEWMAN WC, Goldberg J, Guadix SW, Brown S, et al
    The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes.
    J Neurooncol. 2021 Jun 19. pii: 10.1007/s11060-021-03790.
    PubMed     Abstract available

  420. ROSSO DA, Rosato M, Iturrizaga J, Gonzalez N, et al
    Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated gammadelta T lymphocytes.
    J Neurooncol. 2021 Jun 14. pii: 10.1007/s11060-021-03787.
    PubMed     Abstract available

  421. LIU IH, Holtzman AL, Rotondo RL, Indelicato DJ, et al
    Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
    J Neurooncol. 2021 Jun 8. pii: 10.1007/s11060-021-03783.
    PubMed     Abstract available

  422. CASTRO M, Pampana A, Alam A, Parashar R, et al
    Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
    J Neurooncol. 2021 Jun 8. pii: 10.1007/s11060-021-03780.
    PubMed     Abstract available

  423. CHEN YL, Huang AP, Wang CC, Chen HY, et al
    Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis.
    J Neurooncol. 2021 Jun 7. pii: 10.1007/s11060-021-03782.
    PubMed     Abstract available

  424. ADELON J, Dufour C, Foulon S, Masliah Planchon J, et al
    What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?
    J Neurooncol. 2021 Jun 2. pii: 10.1007/s11060-021-03777.
    PubMed     Abstract available

  425. LEE MH, Hur KY, Hong SD, Seol HJ, et al
    Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.
    J Neurooncol. 2021;153:343-350.
    PubMed     Abstract available

  426. RODRIGUES A, Bhambhvani H, Medress ZA, Malhotra S, et al
    Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas.
    J Neurooncol. 2021;153:321-330.
    PubMed     Abstract available

  427. SHEEHAN D, Sheehan K, Sheehan J
    Sonodynamic therapy for metastatic melanoma to the brain.
    J Neurooncol. 2021;153:373-374.

  428. WELLER J, Katzendobler S, Karschnia P, Lietke S, et al
    PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
    J Neurooncol. 2021;153:283-291.
    PubMed     Abstract available

    May 2021
  429. EICHBERG DG, Slepak TI, Pascoini AL, Komotar RJ, et al
    Genetic manipulation of adhesion GPCR CD97/ADGRE5 modulates invasion in patient-derived glioma stem cells.
    J Neurooncol. 2021 May 24. pii: 10.1007/s11060-021-03778.
    PubMed     Abstract available

  430. DIJKSTRA BM, de Jong M, Stroet MCM, Andreae F, et al
    Correction to: Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
    J Neurooncol. 2021 May 20. pii: 10.1007/s11060-021-03769.

  431. MOTOMURA K, Chalise L, Ohka F, Aoki K, et al
    Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
    J Neurooncol. 2021 May 19. pii: 10.1007/s11060-021-03776.
    PubMed     Abstract available

  432. OYA S, Ikawa F, Ichihara N, Wanibuchi M, et al
    Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma: a propensity score matching analysis of the Brain Tumor Registry of Japan.
    J Neurooncol. 2021 May 17. pii: 10.1007/s11060-021-03775.
    PubMed     Abstract available

  433. ZHONG J, Huang V, Gurbani SS, Ramesh K, et al
    3D whole-brain metabolite imaging to improve characterization of low-to-intermediate grade gliomas.
    J Neurooncol. 2021 May 13. pii: 10.1007/s11060-021-03770.
    PubMed     Abstract available

  434. FATIMA N, Shin JH, Curry WT, Chang SD, et al
    Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system.
    J Neurooncol. 2021 May 10. pii: 10.1007/s11060-021-03773.
    PubMed     Abstract available

  435. KRAUSS WE, Yolcu YU, Alvi MA, Moinuddin FM, et al
    Clinical characteristics and management differences for grade II and III spinal meningiomas.
    J Neurooncol. 2021 May 10. pii: 10.1007/s11060-021-03771.
    PubMed     Abstract available

  436. CROTTY EE, Smith SMC, Brasel K, Pakiam F, et al
    Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
    J Neurooncol. 2021 May 8. pii: 10.1007/s11060-021-03767.
    PubMed     Abstract available

  437. EL-KHOULY FE, Veldhuijzen van Zanten SEM, Jansen MHA, Bakker DP, et al
    A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
    J Neurooncol. 2021 May 7. pii: 10.1007/s11060-021-03763.
    PubMed     Abstract available

  438. CORONA AM, Di L, Shah AH, Crespo R, et al
    Current experimental therapies for atypical and malignant meningiomas.
    J Neurooncol. 2021 May 5. pii: 10.1007/s11060-021-03759.
    PubMed     Abstract available

  439. RUTTENS D, Messiaen J, Ferster A, Piette C, et al
    Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience.
    J Neurooncol. 2021 May 3. pii: 10.1007/s11060-021-03766.
    PubMed     Abstract available

  440. SANDLER CX, Matsuyama M, Jones TL, Bashford J, et al
    Physical activity and exercise in adults diagnosed with primary brain cancer: a systematic review.
    J Neurooncol. 2021;153:1-14.
    PubMed     Abstract available

  441. BENDER K, Perez E, Chirica M, Onken J, et al
    High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity.
    J Neurooncol. 2021;153:109-120.
    PubMed     Abstract available

  442. ELTOBGY M, Huntoon K, Musgrave N, Shaikhouni A, et al
    Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir.
    J Neurooncol. 2021;153:161-167.
    PubMed     Abstract available

  443. RAUCH M, Tausch D, Stera S, Blanck O, et al
    MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics.
    J Neurooncol. 2021;153:79-87.
    PubMed     Abstract available

  444. NIEBLAS-BEDOLLA E, Christophers B, Williams JR, Power-Hays A, et al
    Racial and ethnic disparities among children with primary central nervous system tumors in the US.
    J Neurooncol. 2021;152:451-466.
    PubMed     Abstract available

  445. LEE CY, Soliman H, Bragagnolo ND, Sahgal A, et al
    Predicting response to radiotherapy of intracranial metastases with hyperpolarized [Formula: see text]C MRI.
    J Neurooncol. 2021;152:551-557.
    PubMed     Abstract available

  446. MONTERO AS, Tran S, Amelot A, Berriat F, et al
    Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients.
    J Neurooncol. 2021;152:491-499.
    PubMed     Abstract available

    April 2021
  447. DASGUPTA A, Geraghty B, Maralani PJ, Malik N, et al
    Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema.
    J Neurooncol. 2021 Apr 27. pii: 10.1007/s11060-021-03762.
    PubMed     Abstract available

  448. AVADIAPPAN S, Morrison MA, Jakary A, Felton E, et al
    Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy.
    J Neurooncol. 2021 Apr 24. pii: 10.1007/s11060-021-03753.
    PubMed     Abstract available

  449. SONG J, Aljabab S, Abduljabbar L, Tseng YD, et al
    Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy.
    J Neurooncol. 2021 Apr 22. pii: 10.1007/s11060-021-03758.
    PubMed     Abstract available

  450. GILLESPIE CS, Islim AI, Taweel BA, Millward CP, et al
    The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring.
    J Neurooncol. 2021 Apr 22. pii: 10.1007/s11060-021-03761.
    PubMed     Abstract available

  451. DONO A, Mitra S, Shah M, Takayasu T, et al
    PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
    J Neurooncol. 2021 Apr 21. pii: 10.1007/s11060-021-03755.
    PubMed     Abstract available

  452. CHO YA, Kim D, Lee B, Shim JH, et al
    Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
    J Neurooncol. 2021 Apr 17. pii: 10.1007/s11060-021-03710.
    PubMed     Abstract available

  453. O'KEEFFE D, Bambury RM, O'Reilly S
    High grade glioma and caregiver burden.
    J Neurooncol. 2021 Apr 15. pii: 10.1007/s11060-021-03754.

  454. SCHEURING UJ, Ritter S, Martin D, Schackert G, et al
    GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo.
    J Neurooncol. 2021 Apr 15. pii: 10.1007/s11060-021-03737.
    PubMed     Abstract available

  455. RUSTE V, Sunyach MP, Tanguy R, Jouanneau E, et al
    Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
    J Neurooncol. 2021 Apr 10. pii: 10.1007/s11060-021-03751.
    PubMed     Abstract available

  456. VAN DER MEER PB, Koekkoek JAF, van den Bent MJ, Dirven L, et al
    Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints.
    J Neurooncol. 2021 Apr 6. pii: 10.1007/s11060-021-03747.
    PubMed     Abstract available

  457. RUTENBERG MS, Rotondo RL, Rao D, Holtzman AL, et al
    Correction to: Clinical outcomes following proton therapy for adult craniopharyngioma: a singleinstitution cohort study.
    J Neurooncol. 2021;152:415.

  458. BARONI LV, Oller A, Freytes CS, Sampor CV, et al
    Intracranial germ cells tumour: a single institution experience in Argentina.
    J Neurooncol. 2021;152:363-372.
    PubMed     Abstract available

  459. ZHANG L, Chen W, Ding C, Hu Y, et al
    Gamma Knife radiosurgery as the initial treatment for elderly patients with nonfunctioning pituitary adenomas.
    J Neurooncol. 2021;152:257-264.
    PubMed     Abstract available

  460. CHIBA K, Aihara Y, Kawamata T
    Precise detection of the germinomatous component of intracranial germ cell tumors of the basal ganglia and thalamus using placental alkaline phosphatase in cerebrospinal fluid.
    J Neurooncol. 2021;152:405-413.
    PubMed     Abstract available

  461. VAN DER MEULEN M, Dirven L, Bakunina K, van den Bent MJ, et al
    MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
    J Neurooncol. 2021;152:357-362.
    PubMed     Abstract available

  462. TORDJMAN M, Madelin G, Gupta PK, Cordova C, et al
    Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients.
    J Neurooncol. 2021;152:347-355.
    PubMed     Abstract available

  463. ASHER AL, Alvi MA, Bydon M, Pouratian N, et al
    Local failure after stereotactic radiosurgery (SRS) for intracranial metastasis: analysis from a cooperative, prospective national registry.
    J Neurooncol. 2021;152:299-311.
    PubMed     Abstract available

    March 2021
  464. BRENNAN PM, Borchert R, Coulter C, Critchley GR, et al
    Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice.
    J Neurooncol. 2021 Mar 31. pii: 10.1007/s11060-021-03748.
    PubMed     Abstract available

  465. LE VAN T, Graillon T, Jacob J, Vauleon E, et al
    Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
    J Neurooncol. 2021 Mar 28. pii: 10.1007/s11060-021-03741.
    PubMed     Abstract available

  466. MARTINEZ-PEREZ R, Florez-Perdomo W, Freeman L, Ung TH, et al
    Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas.
    J Neurooncol. 2021 Mar 27. pii: 10.1007/s11060-021-03732.
    PubMed     Abstract available

  467. DIJKSTRA BM, de Jong M, Stroet MCM, Andreae F, et al
    Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
    J Neurooncol. 2021 Mar 26. pii: 10.1007/s11060-021-03739.
    PubMed     Abstract available

  468. ARUN S, Ravisankar S, Vanisree AJ
    Correction to: Implication of connexin30 on the stemness of glioma: connexin30 reverses the malignant phenotype of glioma by modulating IGF-1R, CD133 and cMyc.
    J Neurooncol. 2021 Mar 24. pii: 10.1007/s11060-021-03743.

  469. OSTROM QT, Krebs HL, Patil N, Cioffi G, et al
    Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.
    J Neurooncol. 2021 Mar 23. pii: 10.1007/s11060-021-03736.
    PubMed     Abstract available

  470. RITTERBUSCH R, Halasz LM, Graber JJ
    Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy.
    J Neurooncol. 2021 Mar 22. pii: 10.1007/s11060-021-03734.
    PubMed     Abstract available

  471. TABOR JK, Bonda D, LeMonda BC, D'Amico RS, et al
    Neuropsychological outcomes following supratotal resection for high-grade glioma: a review.
    J Neurooncol. 2021 Mar 21. pii: 10.1007/s11060-021-03731.
    PubMed     Abstract available

  472. VERMANDEL M, Dupont C, Lecomte F, Leroy HA, et al
    Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.
    J Neurooncol. 2021 Mar 20. pii: 10.1007/s11060-021-03718.
    PubMed     Abstract available

  473. FULBERT C, Chabardes S, Ratel D
    Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
    J Neurooncol. 2021 Mar 19. pii: 10.1007/s11060-021-03704.
    PubMed     Abstract available

  474. MILLS MN, Thawani C, Figura NB, Oliver DE, et al
    Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases.
    J Neurooncol. 2021 Mar 19. pii: 10.1007/s11060-021-03735.
    PubMed     Abstract available

  475. SHIRVALILOU S, Khoei S, Esfahani AJ, Kamali M, et al
    Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review.
    J Neurooncol. 2021 Mar 13. pii: 10.1007/s11060-021-03729.
    PubMed     Abstract available

  476. MALLA RR, Gopinath S, Gondi CS, Alapati K, et al
    Retraction Note to: uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
    J Neurooncol. 2021 Mar 12. pii: 10.1007/s11060-021-03722.

  477. TATEKAWA H, Uetani H, Hagiwara A, Yao J, et al
    Preferential tumor localization in relation to (18)F-FDOPA uptake for lower-grade gliomas.
    J Neurooncol. 2021 Mar 11. pii: 10.1007/s11060-021-03730.
    PubMed     Abstract available

  478. NAUNG H, Cohen KJ
    An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity.
    J Neurooncol. 2021 Mar 10. pii: 10.1007/s11060-021-03727.
    PubMed     Abstract available

  479. AHN J, Bunevicius A, Sheehan J
    Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report.
    J Neurooncol. 2021 Mar 9. pii: 10.1007/s11060-021-03728.

  480. BURTH S, Ohmann M, Kronsteiner D, Kieser M, et al
    Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
    J Neurooncol. 2021 Mar 5. pii: 10.1007/s11060-021-03716.
    PubMed     Abstract available

  481. PATEL SH, Batchala PP, Muttikkal TJE, Ferrante SS, et al
    Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    J Neurooncol. 2021 Mar 4. pii: 10.1007/s11060-021-03720.
    PubMed     Abstract available

  482. KURDI M, Butt NS, Baeesa S, Alghamdi B, et al
    Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    J Neurooncol. 2021 Mar 4. pii: 10.1007/s11060-021-03723.
    PubMed     Abstract available

  483. MAIR MJ, Kiesel B, Feldmann K, Widhalm G, et al
    LAG-3 expression in the inflammatory microenvironment of glioma.
    J Neurooncol. 2021 Mar 2. pii: 10.1007/s11060-021-03721.
    PubMed     Abstract available

  484. LIM-FAT MJ, Song KW, Iorgulescu JB, Andersen BM, et al
    Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
    J Neurooncol. 2021 Mar 1. pii: 10.1007/s11060-021-03719.
    PubMed     Abstract available

  485. DEWIRE M, Erker C, Hummel TR, Chow LML, et al
    Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers.
    J Neurooncol. 2021;152:107-114.
    PubMed     Abstract available

  486. AMER N, Taha H, Hesham D, Al-Shehaby N, et al
    Aggresomes predict poor outcomes and implicate proteostasis in the pathogenesis of pediatric choroid plexus tumors.
    J Neurooncol. 2021;152:67-78.
    PubMed     Abstract available

    February 2021
  487. UNTERBERGER A, Nguyen T, Duong C, Kondajji A, et al
    Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
    J Neurooncol. 2021 Feb 26. pii: 10.1007/s11060-020-03674.
    PubMed     Abstract available

  488. KRAFT J, Mayinger M, Willmann J, Brown M, et al
    Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology.
    J Neurooncol. 2021 Feb 23. pii: 10.1007/s11060-021-03714.
    PubMed     Abstract available

  489. MOMIN AA, Shao J, Soni P, Almeida JP, et al
    Outcomes of salvage radiation for recurrent world health organization grade II meningiomas: a retrospective cohort study.
    J Neurooncol. 2021 Feb 15. pii: 10.1007/s11060-021-03711.
    PubMed     Abstract available

  490. HOLUB K, Louvel G
    Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
    J Neurooncol. 2021 Feb 15. pii: 10.1007/s11060-021-03712.
    PubMed     Abstract available

  491. CIFARELLI CP, Jacques A, Bobko A
    Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation.
    J Neurooncol. 2021 Feb 10. pii: 10.1007/s11060-021-03707.
    PubMed     Abstract available

  492. BORGER V, Hamed M, Ilic I, Potthoff AL, et al
    Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection.
    J Neurooncol. 2021 Feb 7. pii: 10.1007/s11060-021-03705.
    PubMed     Abstract available

  493. PRZYBYLOWSKI CJ, Hervey-Jumper SL, Sanai N
    Surgical strategy for insular glioma.
    J Neurooncol. 2021;151:491-497.
    PubMed     Abstract available

  494. ROGERS CM, Jones PS, Weinberg JS
    Intraoperative MRI for Brain Tumors.
    J Neurooncol. 2021;151:479-490.
    PubMed     Abstract available

  495. KARIMI S, Mansouri S, Nassiri F, Bunda S, et al
    Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
    J Neurooncol. 2021;151:443-449.
    PubMed     Abstract available

  496. D'AMICO RS, Aghi MK, Vogelbaum MA, Bruce JN, et al
    Convection-enhanced drug delivery for glioblastoma: a review.
    J Neurooncol. 2021;151:415-427.
    PubMed     Abstract available

  497. HOLLON T, Orringer DA
    Label-free brain tumor imaging using Raman-based methods.
    J Neurooncol. 2021;151:393-402.
    PubMed     Abstract available

  498. CHAN HY, Choi J, Jackson C, Lim M, et al
    Combination immunotherapy strategies for glioblastoma.
    J Neurooncol. 2021;151:375-391.
    PubMed     Abstract available

  499. MARTINEZ-PEREZ R, Requena LC, Carrau RL, Prevedello DM, et al
    Modern endoscopic skull base neurosurgery.
    J Neurooncol. 2021;151:461-475.
    PubMed     Abstract available

  500. CHEN C, Lee I, Tatsui C, Elder T, et al
    Laser interstitial thermotherapy (LITT) for the treatment of tumors of the brain and spine: a brief review.
    J Neurooncol. 2021;151:429-442.
    PubMed     Abstract available

  501. LAKOMKIN N, Van Gompel JJ, Post KD, Cho SS, et al
    Fluorescence guided surgery for pituitary adenomas.
    J Neurooncol. 2021;151:403-413.
    PubMed     Abstract available

  502. VOGELBAUM MA, Parney IF, Elder JB, Cahill D, et al
    Neurosurgical involvement in clinical trials for CNS tumors.
    J Neurooncol. 2021;151:367-373.
    PubMed     Abstract available

  503. BANDER ED, Sherman JH, Bettegowda C, Aghi MK, et al
    Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons.
    J Neurooncol. 2021;151:361-366.
    PubMed     Abstract available

  504. REDJAL N, Venteicher AS, Dang D, Sloan A, et al
    Guidelines in the management of CNS tumors.
    J Neurooncol. 2021;151:345-359.
    PubMed     Abstract available

  505. GERMANO IM, Heth J, Jones PS, Aghi MK, et al
    Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors.
    J Neurooncol. 2021;151:341-343.
    PubMed     Abstract available

    January 2021
  506. VAIDYA KS, Mitten MJ, Zelaya-Lazo AL, Oleksijew A, et al
    Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    J Neurooncol. 2021 Jan 30. pii: 10.1007/s11060-021-03703.
    PubMed     Abstract available

  507. MEDIKONDA R, Srivastava S, Kim T, Xia Y, et al
    Development of new brain metastases in triple negative breast cancer.
    J Neurooncol. 2021 Jan 29. pii: 10.1007/s11060-021-03702.
    PubMed     Abstract available

  508. KOMMERS I, Ackermans L, Ardon H, van den Brink WA, et al
    Between-hospital variation in rates of complications and decline of patient performance after glioblastoma surgery in the dutch Quality Registry Neuro Surgery.
    J Neurooncol. 2021 Jan 28. pii: 10.1007/s11060-021-03697.
    PubMed     Abstract available

  509. SAUNDERS JT, Holmes B, Benavides-Serrato A, Kumar S, et al
    Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    J Neurooncol. 2021 Jan 28. pii: 10.1007/s11060-021-03699.
    PubMed     Abstract available

  510. KEBIR S, Rauschenbach L, Weber M, Lazaridis L, et al
    Machine learning-based differentiation between multiple sclerosis and glioma WHO II degrees -IV degrees using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.
    J Neurooncol. 2021 Jan 27. pii: 10.1007/s11060-021-03701.
    PubMed     Abstract available

  511. DONO A, Amsbaugh M, Martir M, Smilie RH, et al
    Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
    J Neurooncol. 2021 Jan 25. pii: 10.1007/s11060-020-03689.
    PubMed     Abstract available

  512. BU L, Hameed NUF, Luo C, Hong P, et al
    Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    J Neurooncol. 2021 Jan 24. pii: 10.1007/s11060-020-03676.
    PubMed     Abstract available

  513. SHARMA A, Fruth B, Barrera C, Farfour HN, et al
    How much time do we have? Longitudinal perception of prognosis in newly-diagnosed high grade glioma patients and caregivers compared to clinicians.
    J Neurooncol. 2021 Jan 23. pii: 10.1007/s11060-021-03700.
    PubMed     Abstract available

  514. PATRIZZ A, Dono A, Zhu P, Tandon N, et al
    Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?
    J Neurooncol. 2021 Jan 22. pii: 10.1007/s11060-020-03690.
    PubMed     Abstract available

  515. HAEREN RHL, Rautalin I, Schwartz C, Korja M, et al
    Surgery on giant meningiomas in very old patients entails frequent postoperative intracranial hemorrhages and atypical histopathology.
    J Neurooncol. 2021 Jan 21. pii: 10.1007/s11060-020-03693.
    PubMed     Abstract available

  516. MALAIZE H, Samoyeau T, Zanello M, Roux A, et al
    Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
    J Neurooncol. 2021 Jan 15. pii: 10.1007/s11060-021-03696.
    PubMed     Abstract available

  517. WEGNER RE, Abel S, D'Amico RS, Mehta GU, et al
    Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
    J Neurooncol. 2021 Jan 11. pii: 10.1007/s11060-020-03663.
    PubMed     Abstract available

  518. NOWAK-CHOI K, Palmer JD, Casey J, Chitale A, et al
    Resected WHO grade I meningioma and predictors of local control.
    J Neurooncol. 2021 Jan 9. pii: 10.1007/s11060-020-03688.
    PubMed     Abstract available

  519. FUJIOKA Y, Hata N, Akagi Y, Kuga D, et al
    Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
    J Neurooncol. 2021 Jan 8. pii: 10.1007/s11060-020-03682.
    PubMed     Abstract available

  520. ZHANG M, Rodrigues AJ, Pollom EL, Gibbs IC, et al
    Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    J Neurooncol. 2021 Jan 7. pii: 10.1007/s11060-020-03686.
    PubMed     Abstract available

  521. GOMES I, Moreno DA, Dos Reis MB, da Silva LS, et al
    Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    J Neurooncol. 2021 Jan 5. pii: 10.1007/s11060-020-03675.
    PubMed     Abstract available

  522. SHI W, Blumenthal DT, Bush NAO, Kebir S, et al
    Correction to: Global postmarketing safety surveillance of Tumor Treating Fields (TTFields) in patients with highgrade glioma in clinical practice.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03681.

  523. OLIVA MA, Staffieri S, Castaldo S, Giangaspero F, et al
    Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03673.
    PubMed     Abstract available

  524. BRAHMBHATT N, Stupp R, Bushara O, Bachman E, et al
    Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03664.
    PubMed     Abstract available

  525. WUMMER B, Woodworth D, Flores C
    Brain stem gliomas and current landscape.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03655.
    PubMed     Abstract available

  526. HABIB A, Pease M, Kodavali CV, Amankulor N, et al
    A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03671.
    PubMed     Abstract available

  527. CHAMPEAUX-DEPOND C, Weller J, Froelich S, Sartor A, et al
    Cyproterone acetate and meningioma: a nationwide-wide population based study.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03672.
    PubMed     Abstract available

  528. CLAVREUL A, Aubin G, Delion M, Lemee JM, et al
    What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients?
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03666.
    PubMed     Abstract available

  529. VANMARCKE D, Menten J, Defraene G, Van Calenbergh F, et al
    Stroke rate after external fractionated radiotherapy for benign meningioma.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03678.
    PubMed     Abstract available

  530. SAMARUT E, Lugat A, Amelot A, Scharbarg E, et al
    Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03683.
    PubMed     Abstract available

  531. NIMBALKAR VP, Kruthika BS, Sravya P, Rao S, et al
    Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03685.
    PubMed     Abstract available

  532. BUNK EC, Wagner A, Stummer W, Senner V, et al
    5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03680.
    PubMed     Abstract available

  533. HADDAD AF, Young JS, Mummaneni NV, Kasahara N, et al
    Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03684.
    PubMed     Abstract available

  534. LEE D, Riestenberg RA, Haskell-Mendoza A, Bloch O, et al
    Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03677.
    PubMed     Abstract available

  535. LO YT, Ang YLS, Yang VS, Kanavathy DT, et al
    Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas.
    J Neurooncol. 2021;151:295-306.
    PubMed     Abstract available

  536. SONI P, Shao J, Momin A, Lopez D, et al
    Clear cell histology portends a worse prognosis than other WHO grade II histologies.
    J Neurooncol. 2021;151:307-312.
    PubMed     Abstract available

  537. BONM AV, Gibson AW, Holmberg LA, Mielcarek M, et al
    A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    J Neurooncol. 2021;151:193-200.
    PubMed     Abstract available

  538. SAMUEL N, Trifiletti DM, Quinones-Hinojosa A, Lunsford LD, et al
    Stereotactic radiosurgery training patterns across neurosurgical programs: a multi-national survey.
    J Neurooncol. 2021;151:325-330.
    PubMed     Abstract available

  539. SAVOOR R, Sita TL, Dahdaleh NS, Helenowski I, et al
    Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases.
    J Neurooncol. 2021;151:241-247.
    PubMed     Abstract available

  540. SARID N, Bokstein F, Blumenthal DT, Weiss-Meilik A, et al
    Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    J Neurooncol. 2021;151:211-220.
    PubMed     Abstract available

  541. BUTENSCHOEN VM, Hubertus V, Janssen IK, Onken J, et al
    Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series.
    J Neurooncol. 2021;151:181-191.
    PubMed     Abstract available

  542. BECCARIA K, Sabbagh A, de Groot J, Canney M, et al
    Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors.
    J Neurooncol. 2021;151:65-73.
    PubMed     Abstract available

    November 2020
  543. FAN KY, Lalani N, LeVasseur N, Krauze A, et al
    Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.
    J Neurooncol. 2020 Nov 18. pii: 10.1007/s11060-020-03657.
    PubMed     Abstract available

  544. POETSCH L, Bronnimann C, Loiseau H, Frenel JS, et al
    Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    J Neurooncol. 2020 Nov 17. pii: 10.1007/s11060-020-03662.
    PubMed     Abstract available

  545. SONI P, Davison MA, Shao J, Momin A, et al
    Extent of resection and survival outcomes in World Health Organization grade II meningiomas.
    J Neurooncol. 2020 Nov 17. pii: 10.1007/s11060-020-03632.
    PubMed     Abstract available

  546. CHAN RW, Chen H, Myrehaug S, Atenafu EG, et al
    Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
    J Neurooncol. 2020 Nov 16. pii: 10.1007/s11060-020-03661.
    PubMed     Abstract available

  547. CHO A, Untersteiner H, Hirschmann D, Fitschek F, et al
    Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients.
    J Neurooncol. 2020 Nov 11. pii: 10.1007/s11060-020-03660.
    PubMed     Abstract available

  548. NAKADA M, Nakajima R, Okita H, Nakade Y, et al
    Awake surgery for right frontal lobe glioma can preserve visuospatial cognition and spatial working memory.
    J Neurooncol. 2020 Nov 2. pii: 10.1007/s11060-020-03656.
    PubMed     Abstract available

  549. FARRELL C, Shi W, Bodman A, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
    J Neurooncol. 2020;150:269-359.
    PubMed     Abstract available

  550. ZIU M, Kim BYS, Jiang W, Ryken T, et al
    The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:215-267.
    PubMed     Abstract available

  551. REDJAL N, Nahed BV, Dietrich J, Kalkanis SN, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
    J Neurooncol. 2020;150:165-213.
    PubMed     Abstract available

  552. VELAZQUEZ VEGA JE, Brat DJ, Ryken TC, Olson JJ, et al
    The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2020;150:143-164.
    PubMed     Abstract available

  553. DOMINO JS, Ormond DR, Germano IM, Sami M, et al
    Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:121-142.
    PubMed     Abstract available

  554. LUNDY P, Domino J, Ryken T, Fouke S, et al
    The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:95-120.
    PubMed     Abstract available

  555. OLSON JJ, Ryken TC
    Congress of neurological surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with newly diagnosed glioblastoma: Introduction and Methods.
    J Neurooncol. 2020;150:87-93.
    PubMed     Abstract available

    October 2020
  556. CHANG L, Wang J, Zhou F, Wang D, et al
    LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1.
    J Neurooncol. 2020 Oct 30. pii: 10.1007/s11060-020-03624.
    PubMed     Abstract available

  557. RAHMAN M, Parney I
    Journal of Neuro Oncology: immunotherapy for brain tumors.
    J Neurooncol. 2020 Oct 20. pii: 10.1007/s11060-020-03589.

  558. ZAMANIPOOR NAJAFABADI AH, van der Meer PB, Boele FW, Taphoorn MJB, et al
    Determinants and predictors for the long-term disease burden of intracranial meningioma patients.
    J Neurooncol. 2020 Oct 19. pii: 10.1007/s11060-020-03650.
    PubMed     Abstract available

  559. HE W, Liu Z, Teng H, Tang L, et al
    Pediatric meningiomas: 10-year experience with 39 patients.
    J Neurooncol. 2020 Oct 16. pii: 10.1007/s11060-020-03649.
    PubMed     Abstract available

  560. MCABEE JH, Degorre-Kerbaul C, Valdez K, Wendler A, et al
    Detection of glioblastoma intratumor heterogeneity in radiosensitivity using patient-derived neurosphere cultures.
    J Neurooncol. 2020 Oct 15. pii: 10.1007/s11060-020-03643.
    PubMed     Abstract available

  561. HIPP SJ, Goldman S, Kaushal A, Krauze A, et al
    A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
    J Neurooncol. 2020 Oct 11. pii: 10.1007/s11060-020-03627.
    PubMed     Abstract available

  562. DEWIRE M, Fuller C, Hummel TR, Chow LML, et al
    A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    J Neurooncol. 2020 Oct 9. pii: 10.1007/s11060-020-03641.
    PubMed     Abstract available

  563. SONG Y, Hu Z, Long H, Peng Y, et al
    Correction to: A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
    J Neurooncol. 2020 Oct 8. pii: 10.1007/s11060-020-03644.
    PubMed     Abstract available

  564. SELT F, van Tilburg CM, Bison B, Sievers P, et al
    Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    J Neurooncol. 2020 Oct 7. pii: 10.1007/s11060-020-03640.
    PubMed     Abstract available

  565. MOROKOFF A, Jones J, Nguyen H, Ma C, et al
    Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma.
    J Neurooncol. 2020 Oct 7. pii: 10.1007/s11060-020-03630.
    PubMed     Abstract available

  566. DE TOMMASI C, Richardson E, Reale M, Jordan J, et al
    Evaluation of a novel application of a mindfulness phone application for patients with brain tumours: a feasibility study.
    J Neurooncol. 2020 Oct 6. pii: 10.1007/s11060-020-03638.
    PubMed     Abstract available

  567. DONO A, Vu J, Anapolsky M, Hines G, et al
    Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    J Neurooncol. 2020 Oct 3. pii: 10.1007/s11060-020-03634.
    PubMed     Abstract available

    September 2020
  568. SCHNEIDER M, Ilic I, Potthoff AL, Hamed M, et al
    Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates.
    J Neurooncol. 2020 Sep 29. pii: 10.1007/s11060-020-03629.
    PubMed     Abstract available

  569. SCHNEIDER M, Potthoff AL, Scharnbock E, Heimann M, et al
    Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival.
    J Neurooncol. 2020 Sep 29. pii: 10.1007/s11060-020-03625.
    PubMed     Abstract available

  570. RAMOS-FRESNEDO A, Domingo RA, Vivas-Buitrago T, Lundy L, et al
    Multiple meningiomas: does quantity matter? a population-based survival analysis with underlined age and sex differences.
    J Neurooncol. 2020 Sep 28. pii: 10.1007/s11060-020-03620.
    PubMed     Abstract available

  571. DI PERRI D, Tanguy R, Malet C, Robert A, et al
    Risk of radiation necrosis after hypofractionated stereotactic radiotherapy (HFSRT) for brain metastases: a single center retrospective study.
    J Neurooncol. 2020 Sep 26. pii: 10.1007/s11060-020-03628.
    PubMed     Abstract available

  572. WEISS SA, Zito C, Tran T, Heishima K, et al
    Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
    J Neurooncol. 2020 Sep 24. pii: 10.1007/s11060-020-03619.
    PubMed     Abstract available

    June 2020
  573. SENEVIRATNE DS, Hadley AR, Peterson JL, Malouff TD, et al
    Assessment of unintended shifts during frame-based stereotactic radiosurgery using cone beam computed tomography image guidance.
    J Neurooncol. 2020;148:273-279.
    PubMed     Abstract available

  574. LIN YY, Wu HM, Yang HC, Chen CJ, et al
    Repeated gamma knife radiosurgery enables longer tumor control in cases of highly-recurrent intracranial ependymoma.
    J Neurooncol. 2020;148:363-372.
    PubMed     Abstract available

  575. BERTAUX M, Houillier C, Edeline V, Habert MO, et al
    Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
    J Neurooncol. 2020;148:343-352.
    PubMed     Abstract available

    May 2020
  576. SULEIMAN M, Bunevicius A, Sheehan J
    Stereotactic radiosurgery for management of recurring Choroid Plexus Metastases from Non-Small Cell Lung Carcinoma.
    J Neurooncol. 2020;148:207-209.

  577. MICHAIEL G, Strother D, Gottardo N, Bartels U, et al
    Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature.
    J Neurooncol. 2020;147:721-730.
    PubMed     Abstract available

  578. WEIDMAN DR, Palasamudram S, Zak M, Whitney R, et al
    The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    J Neurooncol. 2020;147:731-736.
    PubMed     Abstract available

  579. YEUNG JT, Vesely MD, Miyagishima DF
    In silico analysis of the immunological landscape of pituitary adenomas.
    J Neurooncol. 2020;147:595-598.
    PubMed     Abstract available

  580. KANNO H, Yoshizumi T, Shinonaga M, Kubo A, et al
    Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease.
    J Neurooncol. 2020;148:29-38.
    PubMed     Abstract available

  581. MORSHED RA, Reihl SJ, Molinaro AM, Kakaizada S, et al
    The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.
    J Neurooncol. 2020;148:131-139.
    PubMed     Abstract available

  582. CHEN TW, Jan IS, Chang DY, Lin CH, et al
    Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
    J Neurooncol. 2020;148:165-172.
    PubMed     Abstract available

  583. NATHAN NH, Connor M, Sizdahkhani S, Ding L, et al
    Increased 30-day readmission rate after craniotomy for tumor resection at safety net hospitals in small metropolitan areas.
    J Neurooncol. 2020;148:141-154.
    PubMed     Abstract available

  584. THOMAS C, Metrock K, Kordes U, Hasselblatt M, et al
    Epigenetics impacts upon prognosis and clinical management of choroid plexus tumors.
    J Neurooncol. 2020;148:39-45.
    PubMed     Abstract available

  585. MAIR MJ, Wohrer A, Furtner J, Simonovska A, et al
    Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma.
    J Neurooncol. 2020;148:187-198.
    PubMed     Abstract available

  586. WANG H, Wang R, Hu T, Wang Z, et al
    Nonfunctioning pituitary adenomas in pediatric and adolescent patients: a clinical analysis of a series of 14 patients.
    J Neurooncol. 2020;148:179-186.
    PubMed     Abstract available

    April 2020
  587. SHIN DW, Kim JH, Kim YH, Cho YH, et al
    Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis.
    J Neurooncol. 2020;147:339-349.
    PubMed     Abstract available

  588. GUO Y, He X, Zhang M, Qu Y, et al
    Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
    J Neurooncol. 2020;147:327-337.
    PubMed     Abstract available

  589. WILLEKE VM, Anderson MP, Mahadevan A, Rojas R, et al
    Epstein Barr virus associated smooth muscle tumors in the central nervous system: a case report and systematic review of the literature.
    J Neurooncol. 2020;147:247-260.
    PubMed     Abstract available

  590. PATEL MP, Kirkpatrick JP, Johnson MO, Healy P, et al
    Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    J Neurooncol. 2020;147:477-483.
    PubMed     Abstract available

  591. PALMER JD, Bhamidipati D, Shukla G, Epperla N, et al
    Outcomes after stereotactic radiosurgery for CNS lymphoma.
    J Neurooncol. 2020;147:465-476.
    PubMed     Abstract available

  592. D'AMICO RS, Khatri D, Reichman N, Patel NV, et al
    Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
    J Neurooncol. 2020;147:261-278.
    PubMed     Abstract available

  593. GUPTA T, Maitre M, Gupta P, Krishnatry R, et al
    Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma.
    J Neurooncol. 2020;147:405-415.
    PubMed     Abstract available

    March 2020
  594. AMBADY P, Fu R, Szidonya L, Peereboom DM, et al
    Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma.
    J Neurooncol. 2020;147:171-176.
    PubMed     Abstract available

  595. BETTE S, Gradtke CV, Cammardella JH, Albertshauser J, et al
    Perioperative neurocognitive functions in patients with neuroepithelial intracranial tumors.
    J Neurooncol. 2020;147:77-89.
    PubMed     Abstract available

  596. FERREIRA MSV, Sorensen MD, Pusch S, Beier D, et al
    Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    J Neurooncol. 2020;147:1-14.
    PubMed     Abstract available

    January 2020
  597. LUTHER EM, McCarthy D, Berry KM, Rajulapati N, et al
    Hospital teaching status associated with reduced inpatient mortality and perioperative complications in surgical neuro-oncology.
    J Neurooncol. 2020;146:389-396.
    PubMed     Abstract available

  598. NG S, Fomekong F, Delabar V, Jacquesson T, et al
    Current status and treatment modalities in metastases to the pituitary: a systematic review.
    J Neurooncol. 2020;146:219-227.
    PubMed     Abstract available

  599. AHSAN SA, Chendeb K, Briggs RG, Fletcher LR, et al
    Beyond eloquence and onto centrality: a new paradigm in planning supratentorial neurosurgery.
    J Neurooncol. 2020;146:229-238.
    PubMed     Abstract available

  600. UMEMURA Y, Wang D, Peck KK, Flynn J, et al
    DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.
    J Neurooncol. 2020;146:339-346.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.